

Development of α GlcN(1 \leftrightarrow 1) α Man-Based Lipid A Mimetics as a Novel Class of Potent Toll-like Receptor 4 Agonists

Florian Adanitsch,[‡] Simon Ittig,[#] Johannes Stöckl,[†] Alja Oblak,[§] Mira Haegman,[⊥] Roman Jerala,[§] Rudi Beyaert,[⊥] Paul Kosma,[‡] and Alla Zamyatina*^{‡,§}

[‡]Department of Chemistry, University of Natural Resources and Life Sciences, Muthgasse 18, A-1190 Vienna, Austria


[#]Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland

[†]Institute of Immunology, Medical University of Vienna, Borschkegasse 8a, A-1180 Vienna, Austria

[⊥]Department for Biomedical Molecular Biology, Unit of Molecular Signal Transduction in Inflammation, Inflammation Research Center, VIB, Ghent University, Technologiepark 927, B-9052 Ghent, Belgium

[§]Department of Biotechnology, University of Ljubljana, Hajdrihova 19, 1000 Ljubljana, Slovenia

S Supporting Information



ABSTRACT: The endotoxic portion of lipopolysaccharide (LPS), a glycopospholipid Lipid A, initiates the activation of the Toll-like Receptor 4 (TLR4)–myeloid differentiation factor 2 (MD-2) complex, which results in pro-inflammatory immune signaling. To unveil the structural requirements for TLR4·MD-2-specific ligands, we have developed conformationally restricted Lipid A mimetics wherein the flexible β GlcN(1 \rightarrow 6)GlcN backbone of Lipid A is exchanged for a rigid trehalose-like α GlcN(1 \leftrightarrow 1) α Man scaffold resembling the molecular shape of TLR4·MD-2-bound *E. coli* Lipid A disclosed in the X-ray structure. A convergent synthetic route toward orthogonally protected α GlcN(1 \leftrightarrow 1) α Man disaccharide has been elaborated. The α, α -(1 \leftrightarrow 1) linkage was attained by the glycosylation of 2-*N*-carbamate-protected α -GlcN-lactol with *N*-phenyl-trifluoroacetimidate of 2-*O*-methylated mannose. Regioselective acylation with (*R*)-3-acyloxyacyl fatty acids and successive phosphorylation followed by global deprotection afforded bis- and monophosphorylated hexaacylated Lipid A mimetics. α GlcN(1 \leftrightarrow 1) α Man-based Lipid A mimetics (α, α -GM-LAM) induced potent activation of NF- κ B signaling in hTLR4/hMD-2/CD14-transfected HEK293 cells and robust LPS-like cytokines expression in macrophages and dendritic cells. Thus, restricting the conformational flexibility of Lipid A by fixing the molecular shape of its carbohydrate backbone in the “agonistic” conformation attained by a rigid α GlcN(1 \leftrightarrow 1) α Man scaffold represents an efficient approach toward powerful and adjustable TLR4 activation.

■ INTRODUCTION

Toll-like Receptor 4 (TLR4) is a mammalian transmembrane receptor protein which, in complex with a myeloid differentiation factor 2 (MD-2), detects picomolar concentrations of Gram-negative bacterial endotoxin (or lipopolysaccharide, LPS) (Figure 1A) and initiates an inflammatory signaling cascade aimed at the eradication of bacterial infection.¹ Activation of the innate immune response through TLR4·MD-2·LPS complex was shown to contribute to the pathogenesis of numerous inflammatory, autoimmune, and chronic diseases, such as sepsis syndrome, asthma, arthritis, and cancer, which highlights the

significance of TLR4·MD-2 complex as a therapeutic target.^{2–5} Therapeutic modulation of the innate immune response by intervention with TLR4·MD-2 signaling has grown to a “hot” topic in the past decade.^{4,6} Moreover, activation of TLR4 has been proposed to bridge the innate and adaptive immunity,⁷ emphasizing stimulation of the TLR4·MD-2 complex by nontoxic ligands as a straightforward way to efficient vaccine adjuvants.^{8–10}

Received: June 21, 2014

Published: September 25, 2014




Figure 1. (A) Structure of LPS, with *Re*-LPS and Lipid A. (B) Structures of TLR4 agonist *E. coli* Lipid A and MPLA. (C) Co-crystal structure of *E. coli* *Ra*-LPS-hMD-2-TLR4 (PDB code: 3FXI; only Lipid A portion of LPS is shown for clarity), top and side views. Phe126 (orange) together with 2-*N*-acyl chain (yellow) creates a hydrophobic patch at the dimerization interface with the second TLR4*·MD-2* complex (brown). Positively charged Arg and Lys (blue) at the rim of the binding pocket of MD-2 are involved in the ionic interactions with the Lipid A phosphates. Images were generated with PyMol.

Lipid A, an amphiphilic membrane-bound portion of LPS, represents the major pathogen-associated molecular pattern which drives the activation of TLR4 by binding to the co-receptor protein MD-2 and triggering the dimerization of two TLR4·MD-2·LPS complexes.¹¹ Generally, the binding of hexaacylated bisphosphorylated Lipid A (such as from *Escherichia coli*, Figure 1B) by human TLR4·MD-2 complex results in the efficient activation of the innate immune response, whereas underacylated Lipid A variants are either inactive or antagonistic (such as tetraacylated lipid IVa, or the synthetic drug candidate Eritoran).^{12,13} The co-crystal structures of the *E. coli* *Re*- and *Ra*-LPS with mouse (m) or human (h) MD-2·TLR4 complex, respectively, unravel that only five long-chain acyl residues of the hexaacylated Lipid A are incorporated into the hydrophobic binding pocket of MD-2 whereas the sixth 2-*N*-acyl chain is exposed on the surface of

MD-2 and is involved in the dimerization interface with the second TLR4*·MD-2*·LPS complex (Figure 1C).^{14,15} The Phe126 residue of MD-2 is proposed to stabilize the presentation of an acyl tail on the surface of the protein and to serve as hydrophobic switch allowing dimerization to occur.^{16,17} LPS-driven homodimerization of TLR4·MD-2·LPS complexes initiates recruitment of adaptor proteins to the intracellular TIR (Toll/interleukin-1 receptor) domains of TLR4 which ultimately results in the induction of the intracellular inflammatory signaling cascade.¹⁸ In contrast, submerging of all lipid chains of the ligand into the hydrophobic binding groove of MD-2 results in an efficient binding without initiation of signaling, which is a characteristic feature of TLR4·MD-2 antagonists.^{12,13}

The presence of both 1- and 4'-phosphate groups of Lipid A was shown to be crucial for the efficiency of the dimerization and the potency of the initiated signaling.¹⁹ The absence of 1-phosphate leads to less efficient dimerization^{20,21} and dampened cytokine production while maintaining sufficient TLR4-mediated immune activation and full adjuvant activity, which guided the development of monophosphoryl Lipid A (MPLA), a licensed vaccine adjuvant (Figure 1B).^{8,10}

Despite tremendous intensive research on the interaction of TLR4·MD-2 complex with isolated,^{22,23} genetically engineered,²⁴ and synthetic Lipid A's and analogues,^{25–29} the structure–activity relationships of the LPS-triggered TLR4 activation are not unambiguously established. Minor variations in the length and distribution pattern of fatty acyl chains in Lipid A typically result in dramatic amendment of TLR4-mediated immune signaling^{25–27} which cannot be rationally predicted.

We have addressed the challenges associated with the exploration of structural basis of LPS-induced TLR4 activation by development of a novel type of Lipid A mimetics wherein the flexible β GlcN(1→6)GlcN backbone of Lipid A is replaced by the conformationally restricted (1↔1)-connected disaccharide scaffolds. Notably, all Lipid A analogues synthesized so far were based either on the native β (1→6)-diglucosamine or on the more flexible backbones wherein one or both GlcN residues were replaced by a linear aglycon.^{9,10,27,30} Previously we reported on the synthesis and potent anti-endotoxic activity of tetraacylated Lipid A mimetics derived from the β,α (1↔1)-linked diglucosamine representing an “antagonistically” shaped scaffold.³¹

Taking advantage of a striking similarity between the conformation of the nonreducing sugar trehalose [α Glc(1↔1) α Glc] and the molecular shape of the β (1→6) diglucosamine backbone of TLR4·MD-2-bound agonist *E. coli* Lipid A disclosed in the X-ray structure, we have developed novel agonistic conformationally confined Lipid A mimetics based on the two-bond-linked rigid trehalose-type α GlcN(1↔1) α Man scaffold (Figure 2).

RESULTS AND DISCUSSION

X-ray Structure-Guided Design of α GlcN(1↔1) α Man-Based Lipid A Mimetics. The β (1→6) diglucosamine backbone represents the most conserved part of Lipid A, whereas its acylation and phosphorylation pattern varies within bacterial species.^{22,32} The overall three-dimensional conformation of the intrinsically flexible three-bond-linked β GlcN(1→6)GlcN backbone of Lipid A is determined by the values of the dihedral angles ω , ϕ , and ψ about (1→6) glycosidic and oxymethyl linkages (Figure 3A). Thus, the


α GlcN (1 \leftrightarrow 1) α Man - based Lipid A mimetics

Figure 2. Structure of Lipid A mimetics (α, α -GM-LAMs) 1–3 based on the conformationally confined α GlcN(1 \leftrightarrow 1) α Man scaffold.

relative orientation of GlcN rings can be easily adapted by rotation about glycosidic and oxymethyl linkages via altering the corresponding torsion angles. This permits spontaneous adjustment of the shape of Lipid A to the geometry of the binding pocket of MD-2, which complicates the estimation of the "active" conformation of the ligand in the [Lipid A-MD-2-TLR4]₂ complex. As seen in the co-crystal structures, the proximal (reducing) GlcN ring of MD-2-bound hexaacetylated Lipid A adopts an inclined (or "twisted") orientation which, as we assume, is essential for the exposure of the long-chain 2-*N*-acyl residue on the surface of MD-2 followed by dimerization with the second MD-2-TLR4 complex (Figure 3A,B).³¹

To explore the structural prerequisites needed for an effective receptor complex homodimerization, we have manipulated the flexibility of the carbohydrate backbone of Lipid A by fixing its molecular shape in an "agonistic" conformation. Since the relative spatial arrangement of the two GlcN rings of MD-2-bound agonist *E. coli* Lipid A disclosed in the co-crystal structures^{14,15} resembles the arrangement of α, α -(1 \leftrightarrow 1)-connected glucoses in the nonreducing disaccharide trehalose (Figure 3B,C), we have developed predictably agonistic Lipid A mimetics based on the conformationally confined α, α -trehalose-like α GlcN(1 \leftrightarrow 1) α Man scaffold (Figure 3D).

The values for the torsion angles Φ_α and Φ'_α , representing rings orientation about the α, α -(1 \leftrightarrow 1) glycosidic linkage (Figure 3D), are governed mostly by the anomeric and exo-anomeric effects and are only marginally dependent on the nature of functional groups in variably substituted α, α -trehaloses.³³ The existence of a single conformational minimum with respect to the dihedrals about glycosidic linkage in α, α -trehaloses was confirmed by molecular dynamics simulations,^{33,34} whereas the preferred *gauche-gauche* conformation of the substituted α, α -trehalose³⁵ and its α Glc(1 \leftrightarrow 1) α Man analogue³⁶ was corroborated by X-ray and conformational analysis, respectively. Thus, conformationally restrained α, α -(1 \leftrightarrow 1) glycosidic linkage in α GlcN(1 \leftrightarrow 1) α Man-based Lipid A mimetics would impose a specific relative orientation of sugar rings resembling the molecular shape of the diglucosamine backbone of the agonistic MD-2-bound Lipid A.




Figure 3. X-ray structure-based design of α, α -GM-LAMs. (A) Adjustment of the torsion angles about the (1 \rightarrow 6) glycosidic linkage in the diglucosamine backbone of Lipid A upon binding by MD-2 results in a "twisted" orientation of the proximal GlcN ring for an agonist and in a coplanar orientation of the two GlcN rings for antagonist. (B) The proximal GlcN moiety of MD-2-bound *E. coli* Lipid A (PDB code 3FXI) adopts an inclined orientation which allows the exposure of the 2-*N*-acyl chain.³¹ Image was generated with PyMol. (C) The molecular shape of α, α -trehalose (crystal structure)^{35,37} resembles the three-dimensional arrangement of β GlcN(1 \rightarrow 6)GlcN backbone of the MD-2-bound *E. coli* Lipid A. (D) Structure of α GlcN(1 \leftrightarrow 1) α Man-based Lipid A mimetic (α, α -GM-LAM) 1 and proposed interaction of 1 with MD-2.

α GlcN(1 \leftrightarrow 1) α Man-based Lipid A mimetics (α, α -GM-LAMs) 1–3 were designed such that the acylation and phosphorylation pattern of the nonreducing (distal) GlcN residue of *E. coli* Lipid A remains unaffected, whereas the β (1 \rightarrow 6) glycosidic linkage is substituted by an α, α -(1 \leftrightarrow 1) glycosidic bond and the reducing (proximal) GlcN moiety of natural Lipid A is exchanged for a nonreducing sugar (mannose) having a specific acylation and phosphorylation pattern (Figure 3D). The location of the phosphate functionality at C-6 of the Man residue was selected to closely resemble the positioning of a 1-phosphate group of *E. coli* lipid A at the secondary dimerization interface of the TLR4-MD-2-Lipid A complex (PDB code 3FXI). The site of acylation at the mannose moiety was chosen such that the attachment of the


long-chain (*R*)-3-acyloxyacyl residue at Man C-4 would provide a sufficient hydrophobic patch to support the homodimerization and the interaction with the second TLR4*·MD-2*·ligand complex.

Upon interaction with the receptor complex, the tetra-acylated GlcN unit of α,α -GM-LAMs 1–3 was supposed to be fully accommodated within the hydrophobic pocket of MD-2, whereas the “twisted” mannose ring should be excluded from the binding site on MD-2 such that the two lipid chains at Man C-4 are presented onto the surface of the protein and involved in the secondary dimerization interface (Figure 3D). The axial configuration at C-2 of mannose should provide, according to the crystal structures, a better fitting to the geometry of the binding pocket of MD-2 and, simultaneously, ensure easier stereocontrol in the 1,2-*trans* glycosylation step to α,α (1 \leftrightarrow 1)-linked disaccharide.

Synthetic Strategy. The assembly of α GlcN(1 \leftrightarrow 1) α Man, a 1,1-glycosidically connected (nonreducing) disaccharide, represents a formidable synthetic challenge with regard to simultaneous stereocontrol at two anomeric centers. Typically, approaches involving conventional glycosylation procedures for the synthesis of trehalose provide moderate stereoselectivity and low yields.³⁸ Since we aimed to establish the α,α (1 \leftrightarrow 1) glycosidic linkage between an amino sugar and a *manno*-configured monosaccharide, we could hardly rely on the intramolecular aglycon delivery approach³⁹ or on the versatile synthetic desymmetrization of the natural trehalose.⁴⁰

For the synthesis of bis- and monophosphorylated Lipid A mimetics 1–3 (Figure 2) having non-symmetrically distributed acyloxyacyl functional groups, a convergent approach involving first the preparation of the orthogonally protected α GlcN(1 \leftrightarrow 1) α Man disaccharide scaffold followed by regioselective phosphorylation and acylation with (*R*)-3-acyloxyacyl fatty acids of variable chain lengths was envisaged (Scheme 1).

Scheme 1. Synthetic Strategy toward Hexaacylated α,α -GM-LAMs 1–3




For the assembly of the α GlcN(1 \leftrightarrow 1) α Man backbone, a 2-*N*-carbamate-protected glucosamine-based lactol was chosen as acceptor, and a 2-*O*-levulinoyl (Lev, 4-oxopentanoyl)-protected mannose was selected to serve as glycosyl donor. The participating protecting group at C-2 (Lev) should allow for a preferable 1,2-*trans* mannosylation. Since the 2-*O*-Lev

protection had to be exchanged for a 2-*O*-Me group later in the synthesis, an alternative glycosylation approach using non-participating methyl protection at C-2 of the mannose-based donor was planned to be explored as well.

The 2-*N*-carbamates of variably protected GlcN-based lactols revealed the highest α/β ratio (up to 9:1) of the anomeric 1-*O*H group, which highlighted these intermediates as the most “stereoselective” glycosyl acceptors. Apparently, the presence of a carbamate N–H capable of hydrogen bonding with the axial oxygen at C-1 is responsible for the substantial enrichment with the α -anomer.

Synthesis of α GlcN(1 \leftrightarrow 1) α Man Scaffold. To minimize the number of required orthogonal protecting groups, we intended the use of a GlcN acceptor with the pre-installed phosphate group at C-4, whereas C-6 was permanently and C-3 was temporarily protected. To this end, the 2-*N*-Troc-protected 4,6-di-*O*-benzylidene acetal 4⁴¹ was first acetylated to provide 3-*O*-acetate 5, which was subjected to regioselective reductive opening of benzylidene acetal with Et₃SiH/TfOH in CH₂Cl₂ to furnish 6-*O*-benzylated compound 6 (Scheme 2). Phosphity-


Scheme 2. Synthesis of Glucosamine Lactol Acceptors 8 and 10^a



^aReagents and conditions: (a) Ac₂O, DMAP, pyridine, 97%; (b) Et₃SiH, TfOH, 4 Å MS, –78 °C, CH₂Cl₂, 68%; (c) 1. (BnO)₂PN(*i*Pr)₂, 1*H*-tetrazole, CH₂Cl₂, 2. *m*CPBA, –78 °C, 90%; (d) HF·Py, THF, 91% for 8, 94% for 10; (e) 1. Zn, AcOH, CH₂Cl₂, 2. FmocCl, EtN(*i*Pr)₂, CH₂Cl₂, 89%.

lation of 4-*O*H with bisbenzyl(diisopropylamino)phosphoramidite with 1*H*-tetrazole as catalyst followed by *in situ* oxidation with *meta*-chloroperbenzoic acid (*m*CPBA) afforded phosphotriester 7. Compound 7 was either desilylated at C-1 by treatment with pyridinium hydrofluoride (HF·Py) in THF to provide a 2-*N*-Troc-protected axially configured lactol 8 ($\alpha/\beta = 9:1$) or processed to the 2-*N*-(9-fluorenylmethyl)carbamate (Fmoc)-protected counterpart 9, which was similarly deprotected at C-1 to furnish anomeric lactol 10, again with a high preponderance of the α -anomer ($\alpha/\beta = 9:1$).

The synthesis of the required mannose-based donors commenced with Zemlén deacetylation of the peracetylated thioethyl glycoside 11,⁴² followed by introduction of a 4,6-di-*O*-*tert*-butylsilylene (DTBS) group in 12 (Scheme 3). Regioselective benzylation at C-3 via stannylene acetal intermediate and the agency of benzyl bromide in the presence of (*n*Bu)₄Ni furnished alcohol 13 in 93% yield. The 2-*O*H group was either levulinoyl-protected by reaction with 4-oxopentanoic acid, *N,N'*-diisopropylcarbodiimide (DIC), and a catalytic amount of 4-*N,N'*-(dimethylamino)pyridine (DMAP) to give 2-*O*-levulinyl ester 14 (90%) or methylated by reaction with MeI/NaH in DMF to provide 2-*O*-methyl ether 15 in 84% yield. Anomeric deprotection with *N*-bromosuccinimide (NBS) in aqueous acetone afforded lactols 16 and 17, respectively, which were

Scheme 3. Synthesis of Mannose-Based Donors^a

^aReagents and conditions: (a) 1. NaOMe, MeOH, 2. (tBu)₂Si(OTf)₂, pyridine, DMF, -35 °C, 89%; (b) 1. (nBu)₂SnO, toluene, 2. BnBr, (nBu)₄Ni, DMF, toluene, reflux, 93%; (c) →14: LevOH, DIC, DMAP, CH₂Cl₂, 90%; (d) →15: MeI, NaH, DMF, 84%; (e) NBS, acetone-H₂O, 24:1, 0 °C, 77% for 16 and 89% for 17; (f) →18 and 20: CCl₃CN, DBU, CH₂Cl₂, 0 °C, 90% for 18 and 94% for 20; (g) →19 and 21: CF₃(NPh)CCL, K₂CO₃, acetone, 99% for 19 and 93% for 21.


converted to trichloroacetimidates (TCA) 18 and 20 or to *N*-phenyl-trifluoroacetimidate (NPTFA) donors⁴³ 19 and 21.

The key point in our initial approach was to obtain a good double α -stereoselectivity in the glycosylation reaction between reducing acceptor 8 (α/β = 9:1) and the 2-*O*-levulinoyl-protected imidate donors 18 or 19. The participating levulinoyl group at C-2 of the *manno*-configured donors 18 and 19 should allow for a selective 1,2-*trans* glycosylation. A survey of the literature revealed that a complete α -*manno* selectivity upon application of 2-*O*-Lev-protected mannosyl donors could be obtained with a variety of acceptors.^{44,45}

In an initial glycosylation attempt comprising coupling the TCA donor 18 and acceptor 8 using trimethylsilyl trifluoromethanesulfonate (TMSOTf) as promoter, an orthoester 23 was obtained as the major product (23%) along with a minor proportion of the target α,α -disaccharide 22 (8%) and a concurrently formed donor self-coupling product 24 (Scheme 4A, Supplementary SI-Table 1). With the less reactive NPTFA donor 19 or with the thioethyl donor 14 the formation of the orthoester was not observed; however, the desired product 22 was isolated only in trace amounts.

We have hypothesized that the diminished reactivity of the torsionally disarmed 4,6-di-*O*-cyclic-protected mannose donor was responsible for the glycosylation failure.⁴⁶ Accordingly, the 4,6-di-*O*-DTBS group in 14 was cleaved and substituted for two acetates to provide 25, wherein the C5–C6 bond was unlocked from the disarming *trans-gauche* conformation.^{46,47} To provide consistency with the previously performed imidate-mediated glycosylations, the thioglycoside at C-1 was exchanged for a TCA group to furnish 27 (Scheme 4B). The coupling of 8 and the torsionally unlocked 4,6-di-*O*-acetyl donor 27 resulted in the isolation of the α,α -configured disaccharide 28, albeit in a similarly low yield (8%).

Thereafter, our attention was turned to the apparently low reactivity of the lactol acceptor 8 affected by the H-bonding between the α -1-OH and the carbamate NH groups. To increase the nucleophilicity of the lactol acceptor and to reduce steric constraints, the disarming acetate at C-3 was exchanged for a TBDMS group, and the sterically demanding 2-*N*-Troc group was replaced by Fmoc protection, which provided α -


Scheme 4. Initial Attempts toward the Synthesis of α GlcN(1 \leftrightarrow 1) α Man Scaffold^a

^aReagents and conditions: (a) 1. HF-Py, THF, 2. Ac₂O, DMAP, pyridine, 85%; (b) NBS, acetone-H₂O, 24:1, 0 °C, 89%; (c) CCl₃CN, DBU, CH₂Cl₂, 67%; (d) TMSOTf (0.05 equiv), 4 Å MS, CH₂Cl₂, 0 °C; (e) (CF₃CO)₂O, CF₃COOH, Et₃SiH, CH₂Cl₂, 0 °C, 91%; (f) 1. (BnO)₂PN(*i*Pr)₂, 1*H*-tetrazole, CH₂Cl₂, 2. *m*CPBA, -78 °C, 91%; (g) 1. Zn, AcOH, CH₂Cl₂, 0 °C, 2. FmocCl, EtN(*i*Pr)₂, CH₂Cl₂, 88%; (h) 1. [Ir(COD)(Ph₂MeP)₂]₂PF₆, H₂, THF, 2. I₂, aq. THF, 86%.

lactol acceptor 33. To this end, compound 30, made by a highly selective reductive opening of benzylidene acetal in the allyl glycoside 29,³¹ was phosphorylated at C-4 to give 31 (Scheme 4C). Reductive cleavage of 2-*N*-Troc protection with Zn in acetic acid followed by reaction with Fmoc chloride in the presence of a EtN(*i*Pr)₂ furnished 32, which was anomericly deprotected using [Ir(COD)(Ph₂MeP)₂]₂PF₆-catalyzed isomerization of the allyl group followed by oxidative cleavage of the 1-propenyl group with I₂ in THF-H₂O to afford the “armed” acceptor 33. Reaction of the 2-*O*-levulinoyl TCA donor 18 with 33, however, reproducibly resulted in the formation of the orthoester 34 as the major product (Scheme 4C).

In retrospect, we assume that the failure of the 2-*O*-levulinoyl-protected mannose-based donors to provide the desired α GlcN(1 \leftrightarrow 1) α Man compound in a glycosylation reaction with GlcN-based lactol acceptors was rather related to a particular conformation of the arising trehalose-type α,α -disaccharide. A successful glycosylation would lead to a sterically hindered coupling product 22, having overlapping bulky 2-*N*-Troc/Fmoc groups at the GlcN moiety and a linear

Scheme 5. Synthesis of GlcN(1↔1)Man Disaccharides



4-oxopentanoate (levulinate) ester group at C-2 of mannose, while reciprocal repulsion of the *N*-carbamate and electron-rich levulinoyl groups could contribute as well.

Given the failure of 2-*O*-levulinoyl-protected mannosyl donors to provide the desired coupling products, the participating protecting group at C-2 of mannose was exchanged for the 2-*O*-Me group as in the donors **20** and **21** (Scheme 3). Successful application of non-participating groups in the α -selective mannosylation has been extensively reported.^{48,49} Gratifyingly, the coupling of the 2-*O*-Me-Man imidate donor **21** with the GlcN-lactol acceptor **8** allowed for a much higher isolated yield (51%) of the α,α -disaccharide **35** (Scheme 5, Table 1, entry 2). Owing to the low reactivity of acceptor **8**, the NPTFA donor **21** was found to be superior to the TCA donor **20** due to the propensity of the latter to form substantial amounts of the rearranged glycosylamide **45** (52%), which is characteristic for glycosylations involving acceptors of diminished reactivity (Table 1, entries 1 and 2). The isolation of the α,α -disaccharide **35** was complicated by the concomitant formation of the co-migrating $\alpha\text{GlcN-}\beta\text{Man}$ **38** and $\beta\text{GlcN-}\alpha\text{Man}$ **41** byproducts. Glycosylation of the 2-*N*-Fmoc-protected acceptor **10** by the NPTFA donor **21** afforded a similar isolated yield (52%) of the target α,α -configured disaccharide **36** (Scheme 5, Table 1, entry 3).

Enhancement of the acceptor reactivity by the use of 3-*O*-TBDMS-protected "armed" lactol **33** did not improve the yields in the coupling reactions with either donor **20** or **21** (Table 1, entries 4 and 5), furnishing $\alpha\text{GlcN}(1\leftrightarrow 1)\alpha\text{Man}$ disaccharide **37** in 25% and 50% yield, respectively. The yield of the $\alpha\text{GlcN}(1\leftrightarrow 1)\alpha\text{Man}$ disaccharide was related to the ease of its chromatographic purification, which, in turn, was strongly dependent on the protection group pattern. Since isolation of the 2-*N*-Fmoc-3-*O*-Ac-protected **36** from the mixture of anomeric products was the most straightforward, this disaccharide was chosen for further transformation to the target α,α -GM-LAMs **1-3**.


The configurations at the anomeric centers of the (1↔1)-linked disaccharides were assigned on the basis of ^1H and ^{13}C NMR shifts at the anomeric positions and the $^1J_{\text{C}_1,\text{H}_1}$ coupling constants⁵⁰ (SI-Table 2). To circumvent the severe peak broadening in the ^1H NMR spectrum, the Fmoc group in **42** was replaced by a 2-*N*-acetate to give acetamide **44** appropriate for the unambiguous signal assignment. The α,α -linkage in **35-37** was confirmed by the large $^1J_{\text{C}_1,\text{H}_1}$ coupling constant values of the anomeric carbons ($^1J_{\text{C}_1,\text{H}_1} = 170-174$ Hz for α -manno- and $^1J_{\text{C}_1,\text{H}_1} = 173-178$ Hz for α -gluco-anomers) and by the downfield shifts and the corresponding vicinal proton coupling constants $^3J_{\text{H}_1,\text{H}_2}$ of the anomeric H-1 signals (δ 5.02–5.12, $^3J_{1,2} = 1.5$ Hz for α -manno- and 5.08–5.23, $^3J_{1,2} \approx 3.7$ Hz for α -gluco-anomers).⁵¹ The β -manno linkage in **38-40** was

Table 1. Outcome of (1↔1) Glycosylation Utilizing 2-*O*-Me-Protected Imidate Donors **20** and **21** (Scheme 5)

Donor	Acceptor	Configuration of GlcN(1↔1)Man Product / Yield		
		$\alpha\alpha$	$\alpha\beta$	$\beta\alpha$
1 20 (1.4)	8	35 15%	38 6%	41 3%
2 21 (1.2)	8	35 51%	38 8%	41 3%
3 21 (1.2)	10	36 52%	39 21%	42 5%
4 20 (1.4)	33	37 25%	40 12%	43 4%
5 21 (1)	33	37 50%	40 19%	43 13%

corroborated by the typically smaller $^1J_{\text{C}_1,\text{H}_1}$ coupling constants for the anomeric carbons ($^1J_{\text{C}_1,\text{H}_1} = 155-157$ Hz) and by the upfield shifts of the anomeric H-1 signals (4.6 ppm) and H-5 signals (3.28 ppm), characteristic for β -mannosides.⁵²

Synthesis of Lipid A Mimetics 1-3 Based on $\alpha\text{GlcN}(1\leftrightarrow 1)\alpha\text{Man}$ Scaffold. Having orthogonally protected $\alpha\text{GlcN}(1\leftrightarrow 1)\alpha\text{Man}$ disaccharide scaffold **36** in hand, we next approached the stepwise deprotection and acylation at C-2 and

Scheme 6. Synthesis of α GlcN(1 \leftrightarrow 1) α Man-Based Lipid A Mimetics (α,α -GM-LAMs) 1–3^a

^aReagents and conditions: (a) aq. 50% NH₂OH, THF, 0 °C: **46** (53%), **47** (2%), **48** (9%), recovered **36** (15%); (b) **49**, DIC, DMAP, CH₂Cl₂, 0 °C, 83%; (c) DBU, CH₂Cl₂; (d) **50**, EDC, CHCl₃; (e) HF·Py, THF; (f) → **57** + **59**, DIC, DMAP, **50**, CH₂Cl₂, 0 °C; (g) → **58** + **60**, DIC, DMAP, **51**, CH₂Cl₂, 0 °C; (h) 1. (BnO)₂PN(*i*Pr)₂, 1H-tetrazole, CH₂Cl₂, 2) *m*CPBA, -78 °C, 91% for **61**, 89% for **62**; (i) Pd black, toluene–MeOH, 1:1, 72% for **1**, 87% for **2**, 81% for **3**.

C-3 of the GlcN fragment. The feasibility of regioselective deacetylation at C-3 in the presence of the adjacent 2-*N*-Fmoc carbamate and the base-labile phosphotriester group at C-4 in **36** was first examined (SI-Scheme 1). Among a variety of tested conditions, application of aqueous hydroxylamine provided the best reproducible results for the exclusive removal of 3-*O*-acetate (SI-Table 3). Cleavage of the 3-*O*-Ac group to furnish **46** was accompanied by the migration of the phosphate from C-4 to the liberated hydroxyl group at C-3 to give **47** (Scheme 6). Besides, a partial hydrolytic loss of one benzyl protecting group in the phosphotriester **46** leading to formation of the phosphodiester **48** was also observed. Further improvements could be achieved through optimization of reaction conditions. Indeed, when the reaction was terminated prior to completion (48 h), the formation of the undesired byproducts **47** and **48** could be largely avoided (2% and 9%, respectively), providing 3-*O*-deacetylated compound **46** in 53% yield (SI-Table 3). Repeated chromatographic purifications of the disaccharide **46** partly account for the relatively low yield.

The first (*R*)-3-(tetradecanoyloxy)tetradecanoyl residue at C-3 of the GlcN moiety was introduced by reaction of **46** with β -acyloxyacyl acid **49** under the agency of DIC and a catalytic

amount of DMAP to provide **52** in 83% yield (Scheme 6). Notably, strictly equimolar amounts of DIC and fatty acid **49**, and a catalytic quantity of DMAP at 0 °C, had to be applied to suppress the concomitant formation of the co-migrating 3-*O*-tetradecanoyl (**53**) and 3-*O*-alkenoyl (**54**) byproducts (11% and 3%, respectively). Application of higher amounts of DIC and/or fatty acid aimed to accelerate the transformation resulted in augmented formation of **53** and **54**, which could be rationalized by a probable β -elimination or rearrangement⁵³ of the *in situ*-formed *O*-acyloxyacylisourea intermediate. Formation of a 3-*O*-alkanoyl side product similar to **53** in the DIC/DMAP-mediated condensation had been previously reported, though no elimination byproduct such as **54** was detected.³⁰ Since esterification with β -acyloxyacyl fatty acids under Steglich conditions is routinely applied in the synthesis of Lipid A's and analogues which often display high bioactivity at picomolar doses, this finding is of importance for the preparation of Lipid A-based compounds of the uppermost purity.

Subsequent Fmoc cleavage in **52** with DBU followed by EDC-mediated *N*-acylation with (*R*)-3-(dodecanoyloxy)-tetradecanoic acid **50** provided tetraacylated disaccharide **55**. Conversion of 4,6-di-*O*-DTBS derivative **55** into diol **56** was

performed under standard conditions with HF-Py in THF. To introduce acyl and phosphate functional groups at mannose C-4 and C-6, respectively, without additional protecting group manipulation, the regioselectivity of the acylation of the diol **56** with the acyloxyacyl acids **50** or **51** was first examined. Since hydroxyl groups in the substituted trehaloses are known to differ in reactivity due to both steric and electronic effects,^{38,40} we expected that, in a heavily substituted α GlcN(1 \leftrightarrow 1) α Man disaccharide **56**, positions C-4 and C-6 at the Man moiety could be discriminated in a subsequent acylation procedure.

Indeed, the major outcome of DIC/DMAP-mediated acylation of **56** with the acids **50** or **51** was not the intrinsically expected primary 6-OH-derived acylation products, but the 4-*O*-acyloxyacyl derivatives **57** and **58** in 51% and 65% yield, respectively, having a 6-OH group at the mannose unit accessible for the ensuing phosphorylation. Minor amounts of the 4,6-bis-*O*-acylated derivatives **59** and **60** (24% and 13%, respectively) were isolated as well. Although the 6-OH group of the mannose residue in α GlcN(1 \leftrightarrow 1) α Man disaccharide **56** is somewhat remote from the 2-NH of the GlcN moiety, the crystal structures of α,α -trehalose-based compounds indicate spatial proximity of the two groups. Thus, it could be assumed that the intramolecular hydrogen bonding (2-NH^{GlcN}–6-OH^{Man}) exerts an adverse effect on the reactivity of the primary hydroxyl group at Man C-6. Furthermore, the bulkiness of the *in situ*-formed acyloxyacyl-activated ester resulting from the reaction of the fatty acids **50** or **51** with DIC/DMAP could also explain the limited access to the sterically hindered 6-OH group in the α,α -trehalose-like disaccharide **56**.

Next, the free 6-OH group in the hexaacylated disaccharides **57** and **58** was phosphorylated by reaction with dibenzyl-(*N,N'*-diisopropylamino)phosphoramidite in the presence of a mild acid catalyst, 1*H*-tetrazole, and subsequent oxidation with *m*CPBA at -78 °C to furnish the bisphosphorylated hexaacylated products **61** and **62** in 91% and 89% yield, respectively. Final debenzylation by hydrogenation of **57**, **61**, and **62** on Pd-black followed by purification with gel permeation chromatography on Sephadex SX1 in toluene-methanol (2:1) afforded target bisphosphorylated Lipid A mimetics **1** and **2** and a monophosphorylated counterpart **3**. In contrast to native Lipid A, compounds **1** and **2** do not possess a labile anomeric phosphate functionality; consequently, they were isolated and biologically assessed as free acids at the phosphates and could be stored in aqueous solution at 4 °C for several months without any noticeable sign of degradation, which was confirmed by MALDI-TOF analysis.

Activation of TLR4-MD-2 Complex by α,α -GM-LAMs 1–3. The propensity of the α,α -GM-LAMs **1–3** to stimulate TLR4-mediated immune signaling was first assessed in the hTLR4/hMD-2/CD14 transfected human embryonic kidney (HEK) 293 cells (HEK-Blue). Since we were particularly interested in the molecular recognition mechanisms implicated in the binding of LPS by the MD-2·TLR4 complex wherein the Lipid A/*Re*-LPS portion of LPS is exclusively involved, we evaluated the activities of α,α -GM-LAMs **1–3** compared to *E. coli* *Re*-LPS (Figure 1A). It has been previously shown that the minimum structural requirement for the expression of the highest cytokine-inducing potency resides in *Re*-LPS, which entails two 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) residues in addition to Lipid A (Supporting Information, SI-Figure 1A).^{54,55} Moreover, the *Re*-LPS has a defined molecular weight (MW) similar to the MW range for Lipid A mimetics (1.8–2.2

kDa), in contrast to wild-type LPS having variable MW (10–15 kDa), so that the direct comparison of a dose-dependent response between compounds **1–3** and *Re*-LPS is more appropriate. The TLR4-stimulating activity of Lipid A mimetics **1–3** was examined over a wide concentration range by monitoring of the activation of the NF- κ B regulated signal transduction pathway via measuring the induction of secreted embryonic alkaline phosphatase (SEAP) and compared to the responses elicited by *E. coli* *Re*-LPS and SM-MPLA.

Remarkably, the glycosylation at C-6' of Lipid A with Kdo residues was reported to be responsible for the 10–20-fold enhancement of the activity of the Kdo/Kdo2-Lipid A (*Re*-LPS) compared to Lipid A alone in the nanomolar concentration range.^{28,54} Notably, conformationally confined α,α -GM-LAM **2** based on just a disaccharide scaffold displayed NF- κ B activation (EC_{50} = 0.08 nM) similar to those of *Re*-LPS (EC_{50} = 0.04 nM) and *E. coli* LPS (EC_{50} = 0.08 nM, SI-Figure 1A), and the TLR4 saturation plateau was reached at a concentration of 1 ng/mL for both ligands (Figure 4).




Figure 4. Dose-dependent activation of TLR4 signaling in hTLR4/hMD-2/hCD14-transfected HEK293 cells (HEK-Blue) by Lipid A mimetics **1–3** compared to *E. coli* *Re*-LPS and *S. minnesota* MPLA.

Compound **1**, having a 2 \times CH₂-longer acyl side chain at Man C-4 compared with α,α -GM-LAM **2**, was a less efficient activator of NF- κ B (EC_{50} = 0.4 nM), so that its TLR4 saturation plateau was reached at a concentration of 5 ng/mL. Thus, shortening of a lipid side chain at C-4 of the mannose moiety by 2 \times CH₂ resulted in a 5-fold increase of TLR-4 stimulating activity, which underlines the significance of hydrophobic interactions at the dimerization interface. Along this line, synthetic manipulation of the length of the acyl side chain at Man C-4 could be used for fine-tuning of the hTLR4-mediated activity in α,α -GM-LAMs. The monophosphate **3**

was, as expected, significantly less active ($EC_{50} = 31$ nM) than its bisphosphorylated counterpart **1**, but it showed a more potent activation profile than SM-MPLA at concentrations above 10 ng/mL.

Modulation of the Expression of Cytokines by α,α -GM-LAMs 1–3 in Human and Mouse Macrophages.

Lipid A mimetics 1–3 were examined for the ability to initiate the expression of tumor necrosis factor- α (TNF- α), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1) in the human monocytic macrophage-like cell line THP-1, which expresses MD-2, CD14, and a variety of cell surface receptors, including TLR4.

The dose-dependent stimulating activity of synthetic Lipid A mimetics was cytokine-specific, revealing higher potency in the induction of the expression of TNF- α and IL-8 by α,α -GM-LAMs **1** and **2** than by *Re*-LPS/LPS (Figure 5A,B, SI-Figures 2




Figure 5. Dose-dependent expression of cytokines induced by α,α -GM-LAMs 1–3 in human macrophage cell line THP-1 compared to *E. coli Re-LPS*. (A) Production of TNF- α . (B) Induction of the expression of IL-8. (C) Induction of release of MCP-1.

and **3**). The release of MCP-1 induced by α,α -GM-LAM **2** was clearly more effective than the production of this chemokine by *Re*-LPS and compound **1** (Figure 5C). Expression of MyD88-dependent chemokine MCP-1 is associated with the activation of the intracellular TLR4-MD-2 complex.⁵⁶ The dampened induction of the expression of cytokines by α,α -GM-LAM **3** correlates to its chemical structure missing a phosphate group at Man C-6. Our results indicate that both α,α -GM-LAMs **1** and **2** are more potent activators of the MyD88 signaling pathway than *Re*-LPS/LPS (Figure 5, SI-Figure 4).

The ability of Lipid A mimetics 1–3 to induce the production of TNF- α and IL-6 from bone marrow-derived macrophages (BMDM) in mice was subsequently examined and compared to that of synthetic *E. coli* Lipid A and *E. coli* MPLA, which are reliable positive controls due to their chemical purity and homogeneity (Figure 6). The maximum




Figure 6. Induction of expression of TNF- α and IL-6 by Lipid A mimetics 1–3 in mBMDM compared to synthetic *E. coli* Lipid A and *E. coli* MPLA. *E. coli* O111:B4 LPS was used as positive control (1 nM).

level of TNF- α (4000 pg/mL) was detected in BMDM cultivated in the presence of 1 nM α,α -GM-LAM **1** or **2**, whereas the same quantity of the “parent” Lipid A resulted in release of half the amount of TNF- α (2000 pg/mL). On the other hand, monophosphoryl α,α -GM-LAM **3** exhibited a dampened ability to express TNF- α (500 pg/mL) at a concentration of 1 nM. Likewise, 1 nM (1.8 ng/mL) of **1** or **2** triggered the release of a 3-fold higher amount of IL-6 (1500 pg/mL) compared to Lipid A (500 pg/mL). Monophosphate **3** revealed a dose-dependent cytokine induction profile showing only marginal expression level of IL-6 at a concentration of 1 nM but higher IL-6 release than MPLA at concentrations above 1 nM.

TLR4 Stimulating Activities of α,α -GM-LAMs 1 and 3 in Human Dendritic Cells.

To test the impact of selected α,α -GM-LAMs **1** and **3** on maturation of human dendritic cells (hDCs), immature monocyte-derived hDCs were stimulated with **1** and **3** in a wide concentration range or with *E. coli* LPS as positive control. DCs are able to persistently sense pathogen-associated molecular patterns and present antigens to T lymphocytes, thereby initiating an adaptive immune response.⁷ DCs treated with LPS acquired a distinctive morphologic phenotype and, when analyzed by flow cytometry, displayed characteristic markers of mature DCs.

Stimulation of DCs with **1** (1 mg/mL) was as potent as that with LPS in inducing DCs maturation and up-regulation of the co-stimulatory molecules CD86, as well as the antigen-presenting structures MHC class I and MHC class II, which are necessary for the induction of an adaptive immune response (SI-Figure 5). None of the α,α -GM-LAMs exerted cytotoxic effects on DCs, as determined by propidium iodide staining (data not shown).

Activated DCs were examined for the production of pro-inflammatory cytokines TNF- α , IL-6, and IL-12, which contribute to the modulation of the T cell response and innate effector functions.⁵⁷ The release of TNF- α and IL-6 reached nearly maximum levels (attained with 10 ng/mL LPS) at the α,α -GM-LAM 1 concentration of 1 ng/mL (Figure 7A). Also




Figure 7. Expression of cytokines induced by α,α -GM-LAMs 1 and 3 in human dendritic cells. (A) Induction of cytokine production by 1 in DCs. (B) Expression of TNF- α , IL-6, and IL-10 induced by monophosphorylated α,α -GM-LAM 3 compared to its bisphosphorylated counterpart 1. *E. coli* LPS (10 ng/mL) was used as a positive control.

the expression of IL-12, which promotes the development of adaptive immune cells and is involved in coordinating innate and adaptive immunity,⁵⁸ was efficiently induced by α,α -GM-LAM 1, indicating its potential adjuvant capacity. The release of TNF- α , IL-6, and IL-10, a unique cytokine with a wide spectrum of anti-inflammatory effects, in DCs induced by monophosphate 3 was, in agreement with the experiments in the recombinant hTLR4/hMD-2 signaling system, less efficient compared to that induced by 1 (Figure 7B).

CONCLUSIONS AND PERSPECTIVES

We have rationally designed, synthesized, and biologically evaluated an entirely novel type of TLR4 agonists based on the conformationally restrained disaccharide scaffold which mimics the spatial arrangement of (1 \rightarrow 6) diglucosamine backbone of MD-2-bound *E. coli* Lipid A, revealed in the co-crystal structures of the TLR4-MD-2-LPS complexes. A convergent synthetic approach toward the α GlcN(1 \leftrightarrow 1) α Man scaffold and hexaacetylated Lipid A mimetics based thereon has been developed. Orthogonally protected nonreducing α GlcN(1 \leftrightarrow 1) α Man disaccharide was assembled via imidate-mediated glycosylation by taking advantage of the axial orientation of the anomeric OH group in the 2-*N*-carbamate-protected GlcN-lactol acceptors. The protecting group pattern

was fine-tuned to ensure stereospecific α,α -(1 \leftrightarrow 1) glycosylation and to afford efficient isolation of the α,α -disaccharide from the anomeric mixtures. Replacement of the labile anomeric 1-phosphate functionality (as in natural Lipid A) for a primary phosphate group in α,α -GM-LAMs 1 and 2 provides unambiguous advantages with respect to hydrolytic stability.

In spite of the lack of Kdo moieties which were demonstrated to be responsible for a 10–20-fold enhancement of the activity of *Re*-LPS (Kdo-Kdo-Lipid A) compared to Lipid A alone, the NF- κ B activation efficacy and cytokine inducing capacity of bisphosphorylated Lipid A mimetics 1 and 2 in DCs and human macrophages were comparable to or higher than those of *Re*-LPS/LPS. The inherent rigidity of the α,α -(1 \leftrightarrow 1) glycosidic linkage in 1–3 would not allow for extensive conformational adjustment of the α GlcN(1 \leftrightarrow 1) α Man backbone to the shape of the binding pocket of MD-2, such that the three-dimensional arrangement of an α,α -GM-LAM molecule should remain preserved also in the protein-bound state. Accordingly, our results indicate that restricting the flexibility of the carbohydrate backbone of Lipid A in an “agonistic” conformation, as in α,α -GM-LAMs, allows the prearrangement of the phosphate and acyl groups in the “flipped” Man moiety in a defined conformation, which results in a very potent TLR4 activation (SI-Figure 6). The shortening of a secondary acyl chain at Man C-4 and the presence of a phosphate group at Man C-6 significantly enhanced the TLR-4 stimulating activity, which indicates the involvement of these functionalities at the dimerization interface with the second TLR4*·MD-2*·ligand complex and opens opportunities for fine-tuning the activities of α,α -GM-LAMs by chemical modifications.

Since the molecular shape of α GlcN(1 \leftrightarrow 1) α Man-based Lipid A mimetics is believed to resemble the conformation of the MD-2-bound *E. coli* Lipid A in the active [TLR4-MD-2-LPS]₂ complex, further immuno-biological studies of the interaction of α,α -GM-LAMs with TLR4-MD-2 would provide deeper insight into the molecular basis of TLR4 activation by LPS.

Along these lines, application of a conformationally restricted “agonistically” shaped disaccharide scaffold in place of the native β GlcN(1 \rightarrow 6)GlcN Lipid A backbone appears to provide a useful tool for modulation of TLR4-MD-2-mediated immune signaling. Thus, synthetic α GlcN(1 \leftrightarrow 1) α Man-based Lipid A mimetics represent the key structures for the advanced development of pharmaceutically applicable immuno-therapeutics or vaccine adjuvant candidates.

EXPERIMENTAL SECTION

General Synthetic Methods. Reagents and solvents were purchased from commercial suppliers and used without further purification unless otherwise stated. Dichloromethane was distilled from CaH₂ and stored over activated 4 Å molecular sieves (MS). THF was distilled over Na/benzophenone directly prior to use. Other solvents were dried by storage over activated MS for at least 48 h prior to use [toluene (4 Å), acetonitrile (3 Å), and DMF (3 Å)]. Residual moisture was determined by colorimetric titration on a Mitsubishi CA-21 Karl Fischer apparatus and did not exceed 20 ppm for dry solvents. Reactions were monitored by TLC performed on silica gel 60 F254 HPTLC pre-coated glass plates with a 25 mm concentration zone (Merck). Spots were visualized by UV light followed by dipping into a H₂SO₄-*p*-anisaldehyde solution or a ninhydrin–EtOH solution and subsequent charring at 250 °C. Solvents were removed under reduced pressure at \leq 30 °C. Preparative HPLC was performed with linear solvent gradients on a YMC Pack SIL-06 250 \times 20 mm, S-5 μ m, 6 nm

column (Column A, loadings 50–150 mg), or on a YMC Pack SIL-06 250 × 10 mm, 5–5 μm, 6 nm column (Column B, loadings 5–50 mg). Preparative MPLC was performed on silica gel 60 (230–400 mesh, Merck). Size exclusion chromatography was performed on Sephadex LH20 or Bio-Beads SX1 (BioRad) supports. NMR spectra were recorded at 298 K on a Bruker Avance III 600 spectrometer (¹H at 600.22 MHz; ¹³C at 150.92 MHz; ³¹P at 242.97 MHz) or on a Bruker DPX 400 spectrometer (¹H at 400.13 MHz; ¹³C at 100.61 MHz; ³¹P at 161.68 MHz) using standard Bruker NMR software. Chemical shifts are reported in ppm, where ¹H NMR spectra in CDCl₃ are referenced to internal TMS and ¹³C-spectra are referenced to the corresponding solvent signal (77.0 ppm for CDCl₃). NMR spectra in other solvents are referenced to residual solvent signals (for acetone-*d*₆, 2.05 and 29.84 ppm; for MeOD, 3.31 and 49.00 ppm, ¹H and ¹³C NMR, respectively). ³¹P NMR spectra in CDCl₃ are referenced according to IUPAC recommendations from 2001 from a referenced ¹H NMR spectrum. In the disaccharides, the mannose NMR signals are indicated by primes. The purity (>95%) was determined by LC-MS and HRMS. HPLC-MS was performed by injections of 0.01–0.1% CH₃CN solutions into a Shimadzu LC-10AD VP system equipped with two gradient pumps, a degasser, a Shimadzu LCMS 2020 detector, and an AllTech 3300 ELSD detector. Analytes were eluted over a Phenomenex Jupiter 5μ C4 300A column using mobile phase A = H₂O (0.1% HCOOH) and mobile phase B = CH₃CN (0.1% HCOOH) in linear gradients from 5% B to 100% B and a flow rate of 0.5 mL/min. High-resolution mass spectrometry (HRMS) was carried out on 1–10 mg/L acetonitrile solutions via LC-TOF MS (Agilent 1200SL HPLC and Agilent 6210 ESI-TOF, Agilent Technologies). The mass spectrometer was tuned with Agilent tune mix to provide a mass accuracy below 2 ppm. The data were analyzed using Agilent Mass Hunter Software. MALDI-TOF MS was performed in the negative-ion mode using a Bruker Autoflex Speed instrument with 6-aza-2-thiothymine (ATT) as matrix. Optical rotation was measured on a PerkinElmer 243B polarimeter equipped with a Haake water circulation bath and a Haake D1 immersion circulator for temperature control. All [α]_D²⁰ values are reported in units of deg·dm⁻¹·cm³·g⁻¹.

3-O-Benzyl-4,6-O-di-tert-butylsilylene-2-O-methyl- α -D-mannopyranosyl-(1 \leftrightarrow 1)-6-O-benzyl-4-O-[bis(benzyloxy)phosphoryl]-2-deoxy-2-(9-fluorenylmethoxycarbonylamino)- α -D-glucopyranoside (36). A solution of glycosyl donor **21** (613 mg, 1.03 mmol) and acceptor **10** (596 mg, 0.751 mmol) in dry CH₂Cl₂ (22 mL) was stirred with powdered activated 4 Å molecular sieves at room temperature (r.t.) for 1 h under an atmosphere of Ar. The mixture was cooled to 0 °C, and a solution of TMSOTf (9 μL, 52 μmol) in dry CH₂Cl₂ (450 μL of a stock solution prepared from 20 μL of TMSOTf in 1 mL of CH₂Cl₂) was added. The mixture was stirred at 0 °C for 30 min, and the reaction was quenched by addition of saturated aqueous (sat. aq.) NaHCO₃ (2 mL). The mixture was warmed to r.t. and diluted with EtOAc (100 mL), the solids were removed by filtration over a pad of Celite, and the filtrate was concentrated. The residue was purified by MPLC (two successive columns: toluene–EtOAc, 4:1→1:1→0:1 followed by hexane–EtOAc, 3:1→2:1) to afford **36** (469 mg, 391 μmol, 52%), **39** (186 mg, 155 μmol, 20%), and **42** (44 mg, 37 μmol, 5%). Disaccharide **36**: *R*_f = 0.32 (hexane–EtOAc, 1:1); [α]_D²⁰ = +61 (c 0.9, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.76–7.75 (m, 2H, arom), 7.57–7.56 (m, 1H, arom.), 7.52–7.51 (m, 1H, arom), 7.45–7.23 (m, 24H, arom), 5.23 (t, 1H, ³J_{3,2} = ³J_{3,4} = 10.0 Hz, H-3), 5.20 (d, 1H, ³J_{1,2} = 3.5 Hz, H-1), 5.12 (s, 1H, H-1'), 5.03 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.99–4.93 (m, 4H, OP(O)(OCH₂Ph)₂), 4.90 (d, 1H, ³J_{NH,2} = 9.6 Hz, NH), 4.82 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.53–4.47 (m, 2H, H-4, CH₂, Fmoc), 4.52 (AB, 1H, ²J = 11.7 Hz, CH₂Ph), 4.44 (AB, 1H, ²J = 11.8 Hz, CH₂Ph), 4.32 (t, 1H, ³J_{4,3'} = ³J_{4,5'} = 9.5 Hz, H-4'), 4.20 (t, 1H, ³J = 7.4 Hz, CH, Fmoc), 4.10–4.07 (m, 2H, H-2, CH₂, Fmoc), 4.05 (dd, 1H, ³J_{6a',5'} = 4.8 Hz, ²J_{6a',6b'} = 10.3 Hz, H-6a'), 3.96 (t, 1H, ³J_{6b',5'} = ²J_{6b',6a'} = 10.3 Hz, H-6b'), 3.79–3.76 (m, 2H, H-5, H-6a), 3.72–3.68 (m, 2H, H-3', H-5'), 3.63 (dd, 1H, ²J = 5.9 Hz, 11.0 Hz, H-6b), 3.41 (s, 1H, H-2'), 3.40 (s, 3H, CH₃, Me), 1.87 (s, 3H, CH₃, Ac), 1.06 (s, 9H, 3×CH₃, DTBS), 0.96 (s, 9H, 3×CH₃, DTBS); ¹³C NMR (151 MHz, CDCl₃) δ 171.58 (CO, Ac), 155.69 (CO, Fmoc), 143.79, 143.47, 141.23, 141.20 (4×Cq, Fmoc), 138.73, 137.78

(2×Cq, CH₂Ph), 135.46 (Cq, ³J_{C,P} = 6.8 Hz, OP(O)(OCH₂Ph)₂), 135.39 (Cq, ³J_{C,P} = 7.3 Hz, OP(O)(OCH₂Ph)₂), 128.72, 128.63, 128.36, 128.32, 128.01, 127.94, 127.79, 127.77, 127.70, 127.67, 127.61, 127.14, 125.12, 125.02, 120.00 (28×CH, arom), 93.70 (C-1', ¹J_{C,H} = 173 Hz), 93.07 (C-1, ¹J_{C,H} = 172 Hz), 79.59 (C-2'), 77.84 (C-3'), 74.78 (C-4'), 74.03 (CH₂Ph), 73.55 (CH₂Ph), 73.49 (C-4, ²J_{C4,P} = 5.9 Hz), 71.35 (C-3), 70.63 (C-5, ³J_{C5,P} = 5.9 Hz), 69.70 (OP(O)(OCH₂Ph)₂), 69.66 (OP(O)(OCH₂Ph)₂), 69.19 (C-5'), 68.29 (C-6), 67.70 (CH₂, Fmoc), 66.36 (C-6'), 59.68 (CH₃, Me), 53.65 (C-2), 46.91 (CH, Fmoc), 27.41, 27.04 (6×CH₃, DTBS), 22.56 (Cq, DTBS), 20.70 (CH₃, Ac), 19.79 (Cq, DTBS); ³¹P NMR (243 MHz, CDCl₃) δ –2.02; HRMS (ESI) *m/z* calcd for C₆₆H₇₈NO₁₆PSi+H⁺ 1200.4900 [M+H⁺], found 1200.4900.

3-O-Benzyl-4,6-O-di-tert-butylsilylene-2-O-methyl- α -D-mannopyranosyl-(1 \leftrightarrow 1)-6-O-benzyl-4-O-[bis(benzyloxy)phosphoryl]-2-deoxy-2-(9-fluorenylmethoxycarbonylamino)- α -D-glucopyranoside (46). A biphasic mixture of **36** (192 mg, 160 μmol) in THF (4 mL) and aq. hydroxylamine (50%, 4 mL) was vigorously stirred at 0 °C for 48 h. The mixture was diluted with EtOAc (50 mL) and washed with aq. citric acid (0.25 M, 70 mL), sat. aq. NaHCO₃ (50 mL), and brine (50 mL). The organic layer was dried over MgSO₄, filtered, and concentrated. The residue was purified by HPLC (two successive columns: toluene–EtOAc, 1:1, and hexane–EtOAc, 3:1→1:1, Column A) to afford **46**, unreacted **36** (56%), **47**, and **48**. The recovered **36** (108 mg, 90 μmol) was subjected to two additional reaction cycles to afford, after isolation by HPLC, compounds **46** (overall yield: 99 mg, 85 μmol, 53%), **47** (4 mg, 3.5 μmol, 2%), and **48** (16 mg, 15 μmol, 9%). Disaccharide **46**: *R*_f = 0.60 (toluene–EtOAc, 1:1); [α]_D²⁰ = +72 (c 1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.76–7.75 (m, 2H, arom), 7.61–7.58 (m, 2H, arom), 7.41–7.23 (m, 24H, arom), 5.25 (s, 1H, H-1), 5.09–4.99 (m, 6H, H-1', CH₂Ph, OP(O)(OCH₂Ph)₂), 4.79–4.74 (m, 2H, CH₂Ph, NH), 4.63–4.56 (m, 1H, CH₂, Fmoc), 4.47 (s, 2H, CH₂Ph), 4.32 (t, 1H, ²J = 9.4 Hz, H-4'), 4.28–4.22 (m, 2H, H-4, CH, Fmoc), 4.19–4.13 (m, 1H, CH₂, Fmoc), 4.07–4.05 (m, 1H, H-6a'), 3.98–3.88 (m, 1H, H-2), 3.95 (t, 1H, ²J = 10.4 Hz, H-6b'), 3.81–3.75 (m, 1H, H-3), 3.71 (td, ²J = 4.8 Hz, ³J = 10.1 Hz, H-5'), 3.69–3.60 (m, 3H, H-3', H-5, H-6a), 3.55 (dd, ²J = 5.2 Hz, ³J = 10.9 Hz, H-6b), 3.40 (s, 3H, CH₃, Me), 3.36 (s, 1H, H-2'), 1.06 (s, 9H, 3×CH₃, DTBS), 0.95 (s, 9H, 3×CH₃, DTBS); ¹³C NMR (151 MHz, CDCl₃) δ 143.87, 143.78, 141.27, 141.25 (4×Cq, Fmoc), 138.84, 137.77 (2×Cq, CH₂Ph), 135.28, 135.24 (2×Cq, OP(O)(OCH₂Ph)₂), 128.91, 128.78, 128.73, 128.65, 128.36, 128.24, 127.93, 127.84, 127.73, 127.71, 127.67, 127.58, 127.17, 127.08, 125.32, 125.19, 119.96, 119.95 (28×CH, arom), 93.81 (C-1'), 93.48 (C-1), 79.81 (C-2'), 77.69 (C-3'), 74.83 (C-4'), 73.84, 73.63 (2×CH₂Ph), 70.98 (C-3), 70.49, 70.32 (C-5, ²J_{C,P} = 8.9 Hz, OP(O)(OCH₂Ph)₂, ²J_{C,P} = 5.7 Hz), 70.04 (OP(O)(OCH₂Ph)₂, ²J_{C,P} = 5.6 Hz), 69.20 (C-5'), 68.36 (C-6), 67.59 (CH₂, Fmoc), 66.40 (C-6'), 59.61 (CH₃, Me), 54.79 (C-2), 47.14 (CH₂, Fmoc), 27.46, 27.06 (6×CH₃, DTBS), 22.59, 19.81 (2×Cq, DTBS); ³¹P NMR (243 MHz, CDCl₃) δ 0.43; HRMS (ESI) *m/z* calcd for C₆₄H₇₆NO₁₅PSi+H⁺ 1158.4795 [M+H⁺], found 1158.4790.

3-O-Benzyl-4,6-O-di-tert-butylsilylene-2-O-methyl- α -D-mannopyranosyl-(1 \leftrightarrow 1)-6-O-benzyl-4-O-[bis(benzyloxy)phosphoryl]-2-deoxy-2-(9-fluorenylmethoxycarbonylamino)-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]- α -D-glucopyranoside (52). To a stirred solution of **46** (95 mg, 82 μmol) in dry CH₂Cl₂ (500 μL) were added solutions of **49** (37 mg, 82 μmol) in dry CH₂Cl₂ (200 μL), DMAP (1 mg, 8 μmol) in dry CH₂Cl₂ (90 μL) of a stock solution 11 mg of DMAP in 1 mL of CH₂Cl₂, and DIC (10 mg, 82 μmol) in dry CH₂Cl₂ (150 μL) at 0 °C, and the mixture was stirred for 2.5 h. Then additional portions of **49** (37 mg, 82 μmol) and DIC (10 mg, 82 μmol) were added, and the mixture was stirred for 4.5 h at 0 °C, diluted with EtOAc (50 mL), and washed with aq. citric acid (0.25 M, 50 mL), sat. aq. NaHCO₃ (50 mL), and brine (50 mL). The organic layer was dried over MgSO₄, filtered, and concentrated. The residue was purified by HPLC (hexane–EtOAc, 5:1→3:1) to afford **52** (109 mg, 68 μmol, 83%) as a colorless syrup. Fractions containing byproducts were purified by HPLC (hexane–EtOAc, 4:1→3:1, Column B) to afford **53** (12 mg, 9 μmol, 11%) and **54** (3 mg, 2.2 μmol, 3%). Compound **52**: *R*_f = 0.66 (toluene–EtOAc, 1:1); [α]_D²⁰ =

+44 (c 1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.75–7.74 (m, 2H, arom), 7.59–7.58 (m, 1H, arom), 7.54–7.53 (m, 1H, arom), 7.45–7.43 (m, 2H, arom), 7.40–7.23 (m, 22H, arom), 5.32 (d, 1H, ³J_{NH,2} = 8.5 Hz, NH), 5.27 (d, 1H, ³J_{1,2} = 3.0 Hz, H-1), 5.24 (t, 1H, ³J_{3,4} = ³J_{3,2} = 10.0 Hz, H-3), 5.20–5.16 (m, 1H, β^{Myr}-CH), 5.11 (s, 1H, H-1'), 5.04 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.98–4.94 (m, 4H, OP(O)(OCH₂Ph)₂), 4.81 (AB, 1H, ²J = 11.8 Hz, CH₂Ph), 4.50 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.47–4.41 (m, 2H, H-4, CH₂, Fmoc), 4.41 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.32 (t, 1H, ³J_{4',5'} = ³J_{4',3'} = 9.5 Hz, H-4'), 4.18 (t, 1H, J = 7.4 Hz, CH, Fmoc), 4.15–4.12 (m, 1H, CH₂, Fmoc), 4.08–4.04 (m, 2H, H-2, H-6a'), 3.96 (t, 1H, ³J_{6b',5'} = ²J_{6b',6a'} = 10.2 Hz, H-6b'), 3.80–3.73 (m, 4H, H-3', H-5', H-5, H-6a), 3.61 (dd, 1H, J = 6.0 Hz, J = 11.1 Hz, H-6b), 3.39 (s, 1H, H-2'), 3.38 (s, 3H, CH₃, Me), 2.49 (dd, 1H, ³J = 8.3 Hz, ²J = 16.1 Hz, α^{Myr}-CH₂), 2.40 (dd, 1H, ³J = 4.4 Hz, ²J = 16.1 Hz, α^{Myr}-CH₂), 2.19–2.10 (m, 2H, α^{Myr}-CH₂), 1.54–1.50 (m, 2H, β^{Myr}-CH₂), 1.42–1.35 (m, 2H, γ^{Myr}-CH₂), 1.30–1.06 (m, 38H, 19×CH₂), 1.05 (s, 9H, 3×CH₃, DTBS), 0.94 (s, 9H, 3×CH₃, DTBS), 0.88 (t, 6H, J = 7.1 Hz, 2×ω^{Myr}-CH₃); ¹³C NMR (151 MHz, CDCl₃) δ 173.23, 171.16 (2×CO), 155.91 (CO, Fmoc), 143.74, 143.66, 141.22, 141.19 (4×Cq, Fmoc), 138.83, 137.87 (2×Cq, CH₂Ph), 135.55, 135.51 (2×Cq, OP(O)(OCH₂Ph)₂), 128.71, 128.64, 128.38, 128.33, 128.16, 128.04, 127.94, 127.80, 127.68, 127.66, 127.62, 127.21, 127.18, 125.29, 125.18, 119.95 (28×CH, arom), 94.02 (C-1'), 93.25 (C-1), 79.76 (C-2'), 78.15 (C-3'), 74.84 (C-4'), 74.23 (CH₂Ph), 73.65 (C-4, ²J_{C4,P} = 5.7 Hz), 73.51 (CH₂Ph), 71.21 (C-3), 70.69 (C-5, ³J_{C5,P} = 5.3 Hz), 69.79 (β^{Myr}-CH or C-5'), 69.78 (OP(O)(OCH₂Ph)₂, ²J_{C,P} = 6.5 Hz), 69.74 (OP(O)(OCH₂Ph)₂, ²J_{C,P} = 6.1 Hz), 69.21 (β^{Myr}-CH or C-5'), 68.36 (C-6), 67.92 (CH₂, NHFmoc), 66.40 (C-6'), 59.70 (CH₃, Me), 53.80 (C-2), 47.01 (CH, Fmoc), 38.96 (α^{Myr}-CH₂), 34.37 (α^{Myr}-CH₂), 34.09 (γ^{Myr}-CH₂), 31.91, 29.68, 29.65, 29.62, 29.52, 29.49, 29.38, 29.35, 29.30, 29.17, 27.46, 27.07, 24.98, 22.68 (20×CH₂, 6×CH₃, DTBS), 22.59, 19.79 (2×Cq, DTBS), 14.10 (2×ω^{Myr}-CH₃); ³¹P NMR (243 MHz, CDCl₃) δ -1.71; HRMS (ESI) *m/z* calcd for C₉₂H₁₂₈NO₁₈PSi+Na⁺ 1616.8513 [M+Na⁺], found 1616.8526.

3-O-Benzyl-4,6-O-di-tert-butylsilylene-2-O-methyl-α-D-mannopyranosyl-(1↔1)-6-O-benzyl-4-O-[bis(benzyloxy)phosphoryl]-2-deoxy-2-[(R)-3-(dodecanoyloxy)tetradecanoylamino]-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-α-D-glucopyranoside (55). To a stirred solution of **52** (104 mg, 65 μmol) in dry CH₂Cl₂ (1 mL) was added DBU (20 μL, 134 μmol) at 0 °C, and the stirring was continued for 1.5 h at r.t. The mixture was diluted with EtOAc (25 mL) and washed with aq. citric acid (0.25 M, 25 mL), sat. aq. NaHCO₃ (25 mL), and brine (25 mL). The organic phase was dried over MgSO₄, filtered, and concentrated. The mixture was purified by silica gel chromatography (hexane–EtOAc, 3:1 (0.1% Et₃N)→1:1 (0.1% Et₃N)) to afford the crude amine (78 mg), *R*_f = 0.28 (hexane–EtOAc, 1:1). To a stirred solution of the intermediate amine (78 mg) in dry CHCl₃ (400 μL) were added a solution of **50** (29 mg, 68 μmol) in dry CHCl₃ (150 μL) and a solution of EDC-HCl (13 mg, 68 μmol) in dry CHCl₃ (200 μL) at r.t. The mixture was stirred for 1.5 h, and then additional amounts of **50** (29 mg, 68 μmol) and EDC-HCl (13 mg, 68 μmol) were added. The mixture was stirred for 3 h, diluted with CHCl₃ (30 mL), and washed with water–brine (1:1, 50 mL). The organic phase was dried over MgSO₄, filtered, and concentrated. The residue was purified by MPLC (hexane–EtOAc, 4:1→3:1) to afford **55** (91 mg, 51 μmol, 78% over two steps) as a colorless syrup: *R*_f = 0.44 (hexane–EtOAc, 2:1); [α]_D²⁰ = +35 (c 1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.43–7.42 (m, 2H, CH₂Ph), 7.35–7.22 (m, 18H, CH₂Ph), 6.10 (d, 1H, ³J_{NH,2} = 7.9 Hz, NH), 5.23–5.12 (m, 2H, 2×β^{Myr}-CH), 5.20 (d, 1H, ³J_{1,2} = 3.6 Hz, H-1), 5.17 (dd, ³J_{3,4} = 9.0 Hz, ³J_{3,2} = 11.1 Hz, H-3), 5.08 (d, 1H, ³J_{1,2'} = 1.5 Hz, H-1'), 5.01 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.96–4.92 (m, 4H, 2×CH₂, OP(O)(OCH₂Ph)₂), 4.77 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.48 (AB, 1H, ²J = 11.8 Hz, CH₂Ph), 4.39 (AB, 1H, ²J = 11.8 Hz, CH₂Ph), 4.38–4.35 (m, 1H, H-4), 4.30 (t, ³J_{4',3'} = ³J_{4',5'} = 9.5 Hz, H-4'), 4.25 (ddd, 1H, ³J_{2,1} = 3.6 Hz, ³J_{2,NH} = 7.8 Hz, ³J_{2,3} = 11.2 Hz, H-2), 4.03 (dd, 1H, ³J_{6a',5'} = 5.0 Hz, ²J_{6a',6b'} = 10.3 Hz, H-6a'), 3.93 (t, 1H, ³J_{6b',5'} = ²J_{6b',6a'} = 10.4 Hz, H-6b'), 3.76–3.74 (m, 2H, H-5, H-6a), 3.71 (dd, 1H, ³J_{3,2'} = 3.3 Hz, ³J_{3,4'} = 9.6 Hz, H-3'), 3.63 (td, 1H, ³J_{5',6a'} = 4.9 Hz, ³J_{5',4'} = ³J_{5',6b'} = 9.9 Hz, H-5'), 3.56

(dd, 1H, J = 6.1 Hz, J = 10.8 Hz, H-6b), 3.39 (dd, 1H, ³J_{2',1'} = 1.6 Hz, ³J_{2',3'} = 3.2 Hz, H-2'), 3.34 (s, 3H, CH₃, Me), 2.48–2.32 (m, 4H, 2×α^{Myr}-CH₂), 2.28–2.19 (m, 4H, α^{Myr}-CH₂, α^{Lau}-CH₂), 1.60–1.46 (m, 8H, 2×γ^{Myr}-CH₂, β^{Myr}-CH₂, β^{Lau}-CH₂), 1.28–1.23 (m, 72H, 36×CH₂, fatty acids), 1.07 (s, 9H, 3×CH₃, DTBS), 1.01 (s, 9H, 3×CH₃, DTBS), 0.89–0.86 (m, 12H, 3×ω^{Myr}-CH₃, ω^{Lau}-CH₃); ¹³C NMR (151 MHz, CDCl₃) δ 173.53, 173.26, 171.26, 169.79 (4×CO), 138.90, 137.89 (2×Cq, CH₂Ph) 135.56, 135.51 (2×Cq, OP(O)(OCH₂Ph)₂) 128.71, 128.63, 128.36, 128.31, 128.18, 128.05, 127.85, 127.63, 127.62, 127.59 (20×CH, CH₂Ph), 93.80 (C-1'), 93.11 (C-1), 79.74 (C-2'), 78.25 (C-3'), 74.65 (C-4'), 74.11 (CH₂Ph), 73.86 (C-4), 73.47 (CH₂Ph), 70.90, 70.76 (C-3, C-5), 70.09, 70.01 (2×β^{Myr}-CH), 69.77, 69.75, 69.74, 69.72 (2×CH₂, OP(O)(OCH₂Ph)₂), 69.33 (C-5'), 68.44 (C-6), 66.36 (C-6'), 59.57 (CH₃, Me), 51.66 (C-2), 40.95, 39.29 (2×α^{Myr}-CH₂), 34.58, 34.46 (α^{Myr}-CH₂, α^{Lau}-CH₂, 2×γ^{Myr}-CH₂), 31.93, 31.92, 29.72, 29.69, 29.66, 29.62, 29.57, 29.52, 29.39, 29.36, 29.25, 29.22, 25.26, 25.19, 25.05, 25.04, 22.68 (38×CH₂) 27.53, 27.29 (6×CH₃, DTBS), 22.64, 19.87 (2×Cq, DTBS), 14.09 (3×ω^{Myr}-CH₃, ω^{Lau}-CH₃); ³¹P NMR (242.97 MHz, CDCl₃) δ -1.67; HRMS (ESI) *m/z* calcd for C₁₀₃H₁₆₆NO₁₉PSi+Na⁺ 1780.1453 [M+Na⁺], found 1780.1430.

3-O-Benzyl-2-O-methyl-α-D-mannopyranosyl-(1↔1)-6-O-benzyl-4-O-[bis(benzyloxy)phosphoryl]-2-deoxy-2-[(R)-3-(dodecanoyloxy)tetradecanoylamino]-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-α-D-glucopyranoside (56). To a stirred solution of **55** (91 mg, 51 μmol) in dry THF (3 mL) in a PTFE vial was added a solution of HF-Py (70%, 50 μL) at 0 °C. The mixture was stirred for 30 min at r.t., diluted with EtOAc (20 mL), and washed with sat. aq. NaHCO₃ (30 mL) and brine (30 mL). The organic phase was dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel chromatography (toluene–EtOAc, 3:1) to afford **56** (78 mg, 47 μmol, 92%): *R*_f = 0.22 (toluene–EtOAc, 1:1); [α]_D²⁰ = +41 (c 1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.43–7.22 (m, 20H, CH₂Ph), 6.34 (d, 1H, ³J_{NH,2} = 8.2 Hz, NH), 5.26 (d, 1H, ³J_{1,2} = 3.7 Hz, H-1), 5.22 (dd, 1H, ³J_{3,4} = 9.1 Hz, ³J_{3,2} = 11.0 Hz, H-3), 5.14–5.10 (m, 1H, β^{Myr}-CH), 5.13 (d, 1H, ³J_{1,2'} = 1.6 Hz, H-1'), 5.05–5.01 (m, 1H, β^{Myr}-CH), 4.97–4.93 (m, 4H, 2×CH₂, OP(O)(OCH₂Ph)₂), 4.79 (AB, 1H, ²J = 11.6 Hz, CH₂Ph), 4.73 (AB, 1H, ²J = 11.7 Hz, CH₂Ph), 4.49 (AB, 1H, ²J = 11.8 Hz, CH₂Ph), 4.42 (q, 1H, ³J_{4,3} = ³J_{4,5} = ³J_{H,P} = 9.2 Hz, H-4), 4.40 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.26 (ddd, 1H, ³J_{1,2} = 3.5 Hz, ³J_{2,NH} = 8.0 Hz, ³J_{2,3} = 11.2 Hz, H-2), 3.92–3.88 (m, 1H, H-4'), 3.84–3.79 (m, 2H, H-3', H-6a'), 3.76–3.74 (m, 3H, H-5, H-6a, H-6b'), 3.60–3.56 (m, 2H, H-5', H-6b), 3.30 (s, 3H, CH₃, Me), 3.30–3.28 (m, 1H, H-2'), 2.70 (s, 1H, OH), 2.48–2.42 (m, 3H, α^{Myr}-CH₂), 2.39 (dd, 1H, J = 6.2 Hz, J = 15.3 Hz, α^{Myr}-CH₂), 2.34–2.26 (m, 2H, α^{Lau}-CH₂), 2.23–2.20 (m, 2H, α^{Myr}-CH₂), 1.65–1.46 (m, 8H, 2×γ^{Myr}-CH₂, β^{Myr}-CH₂, β^{Lau}-CH₂), 1.31–1.21 (m, 72H, 36×CH₂), 0.89–0.86 (m, 12H, 3×ω^{Myr}-CH₃, ω^{Lau}-CH₃); ¹³C NMR (151 MHz, CDCl₃) δ 174.65, 173.48, 171.15, 170.08 (4×CO), 138.10, 137.87 (2×Cq, CH₂Ph), 135.47 (2×Cq, OP(O)(OCH₂Ph)₂), 128.72, 128.63, 128.60, 128.31, 128.17, 128.04, 128.01, 127.63, 127.59 (20×CH, CH₂Ph), 93.14 (C-1'), 92.56 (C-1), 78.78 (C-3'), 77.38 (C-2'), 73.76 (C-4, C-5'), 73.48, 72.76 (2×CH₂Ph), 71.33 (β^{Myr}-CH), 71.02 (C-3), 70.62 (C-5, ³J_{C5,P} = 5.0 Hz), 70.01 (β^{Myr}-CH), 69.82 (2×CH₂, OP(O)(OCH₂Ph)₂), 68.42 (C-6), 67.84 (C-4'), 63.04 (C-6'), 59.03 (CH₃, Me), 51.70 (C-2), 41.50, 39.09 (2×α^{Myr}-CH₂), 34.74, 34.60, 34.41, 34.23 (α^{Myr}-CH₂, α^{Lau}-CH₂, 2×γ^{Myr}-CH₂), 31.92, 31.91, 29.70, 29.68, 29.65, 29.61, 29.58, 29.54, 29.47, 29.43, 29.37, 29.34, 29.20, 29.18, 25.28, 25.17, 25.01, 24.99, 22.67 (38×CH₂), 14.08 (3×ω^{Myr}-CH₃, ω^{Lau}-CH₃); ³¹P NMR (243 MHz, CDCl₃) δ -1.80; HRMS (ESI) *m/z* calcd for C₉₅H₁₅₀NO₁₉P+Na⁺ 1663.0432 [M+Na⁺], found 1663.0424.

3-O-Benzyl-4-O-[(R)-3-(dodecanoyloxy)tetradecanoyl]-2-O-methyl-α-D-mannopyranosyl-(1↔1)-6-O-benzyl-4-O-[bis(benzyloxy)phosphoryl]-2-deoxy-2-[(R)-3-(dodecanoyloxy)tetradecanoylamino]-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-α-D-glucopyranoside (57). To a stirred solution of **56** (21 mg, 13 μmol) and DMAP (0.15 mg, 1.3 μmol) in dry CH₂Cl₂ (500 μL) was added a solution of fatty acid **50** (6.5 mg, 15 μmol) in CH₂Cl₂ (50 μL of a stock solution prepared from 26 mg of **50** in 200 μL of CH₂Cl₂). The mixture was cooled to 0 °C, and DIC (1.9 mg, 15.4 μmol) from a 50 mg/mL stock solution in toluene was added dropwise over a period

of 1 h. Then additional amounts of **50** (1.3 mg, 3.1 μmol) and DIC (0.4 mg, 0.3 μmol) from the indicated stock solutions were successively added (DIC was added dropwise over 30 min) at 0 °C. The mixture was diluted with EtOAc (20 mL) and washed with aq. 2 M HCl (20 mL), aq. sat. NaHCO₃ (20 mL), and brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated. The residue was purified by HPLC (two consecutive columns: toluene–EtOAc, 3:1→2:1, and hexane–EtOAc, 3:1→1:1, column B) to afford **57** (13.5 mg, 6.6 μmol , 51%) as a syrup. Fractions containing byproduct **59** were purified by HPLC (hexane–EtOAc, 5:1→3:1) to afford **59** (7.6 mg, 3.1 μmol , 24%) as a syrup. Compound **57**: R_f = 0.27 (hexane–EtOAc, 1:1); $[\alpha]_D^{20}$ = +68 (c 1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.38–7.21 (m, 20H, CH₂Ph), 6.37 (d, 1H, ³J_{NH,2} = 8.2 Hz, NH), 5.24–5.15 (m, 5H, H-1, H-3, H-4', 2 \times β^{Myr} -CH), 5.12 (d, 1H, ³J_{1,2'} = 2.0 Hz, H-1'), 5.07–5.03 (m, 1H, β^{Myr} -CH), 4.97–4.94 (m, 4H, OP(O)(OCH₂Ph)₂), 4.69 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.64 (AB, 1H, ²J = 12.1 Hz, CH₂Ph), 4.48 (AB, 1H, ²J = 11.8 Hz, CH₂Ph), 4.42 (ddd, 1H, ³J_{4,3} = ³J_{4,5} = ³J_{H,P} = 9.3 Hz, H-4), 4.40 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.24 (ddd, 1H, ³J_{2,1} = 3.6 Hz, ³J_{2,NH} = 8.1 Hz, ³J_{2,3} = 11.1 Hz, H-2), 3.94 (dd, 1H, ³J_{3,2'} = 3.1 Hz, ³J_{3,4'} = 9.4 Hz, H-3'), 3.75–3.72 (m, 2H, H-5, H-6a), 3.62–3.55 (m, 4H, H-5', H-6a', H-6b', H-6b), 3.30–3.29 (m, 1H, H-2'), 3.29 (s, 3H, CH₃, Me), 2.60 (dd, 1H, ²J = 7.6 Hz, 15.5 Hz, α^{Myr} -CH₂), 2.54–2.47 (m, 3H, α^{Myr} -CH₂), 2.44 (dd, 1H, ²J = 7.2 Hz, 15.0 Hz, α^{Myr} -CH₂), 2.37 (dd, 1H, ²J = 5.6 Hz, 15.1 Hz, α^{Myr} -CH₂), 2.30–2.27 (m, 2H, α -CH₂), 2.24–2.19 (m, 4H, 2 \times α -CH₂), 1.62–1.48 (m, 12H, β^{Myr} -CH₂, 2 \times β^{Lau} -CH₂, 3 \times ω^{Myr} -CH₂), 1.30–1.22 (m, 106H, 53 \times CH₂), 0.89–0.86 (m, 18H, 4 \times ω^{Myr} -CH₃, 2 \times ω^{Lau} -CH₃); ¹³C NMR (151 MHz, CDCl₃) δ 173.64, 173.40, 173.10, 171.43, 169.93, 169.88 (6 \times CO), 138.01, 137.88 (2 \times Cq, CH₂Ph), 135.55, 135.51 (2 \times Cq, OP(O)(OCH₂Ph)₂), 128.71, 128.64, 128.53, 128.32, 128.12, 128.11, 128.04, 127.93, 127.65, 127.59 (20 \times CH, CH₂Ph), 94.03 (C-1'), 93.51 (C-1), 77.81 (C-2'), 75.89 (C-3'), 73.67 (C-4, ²J_{C₄,P} = 5.8 Hz), 73.49 (CH₂Ph), 72.74 (C-5'), 72.52 (CH₂Ph), 71.09 (C-3), 70.84 (β^{Myr} -CH), 70.69 (C-5, ³J_{C₅,P} = 5.3 Hz), 69.95, 69.88 (2 \times β^{Myr} -CH), 69.77, 69.73 (2 \times CH₂, OP(O)(OCH₂Ph)₂), 68.36 (C-6), 68.35 (C-4'), 61.71 (C-6'), 59.10 (CH₃, Me), 51.81 (C-2), 41.38, 39.16, 39.02 (3 \times α^{Myr} -CH₂), 34.60, 34.53, 34.44, 34.28, 34.05 (α^{Myr} -CH₂, 2 \times α^{Lau} -CH₂, 3 \times γ^{Myr} -CH₂), 31.93, 29.73, 29.70, 29.67, 29.62, 29.60, 29.57, 29.55, 29.54, 29.52, 29.48, 29.42, 29.39, 29.37, 29.36, 29.33, 29.28, 29.20, 25.36, 25.17, 25.10, 25.01, 22.69 (56 \times CH₂), 14.10 (4 \times ω^{Myr} -CH₃, 2 \times ω^{Lau} -CH₃); ³¹P NMR (243 MHz, CDCl₃) δ -1.71; HRMS (ESI) m/z calcd for C₁₂₁H₁₉₈NO₂₂P+Na⁺ 2071.4035 [M+Na⁺], found 2071.4036.

3-O-Benzyl-6-O-[(bis(benzoyloxy)phosphoryl]-4-O-[(R)-3-(dodecanoyloxy)tetradecanoyl]-2-O-methyl- α -mannopyranosyl-(1 \leftrightarrow 1)-6-O-benzyl-4-O-[(bis(benzoyloxy)phosphoryl]-2-deoxy-2-[(R)-3-(dodecanoyloxy)tetradecanoylamino]-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]- α -D-glucopyranoside (61**).** To a stirred solution of **57** (11 mg, 6 μmol) and dibenzyl *N,N*-diisopropylphosphoramidite (10 μL , 25 μmol , 90%) in dry CH₂Cl₂ (400 μL) was added a solution of 1*H*-tetrazole (54 μL , 24 μmol , 0.45 M in CH₃CN) under an atmosphere of Ar. The mixture was stirred for 1 h and then cooled to -78 °C, and a solution of mCPBA (7 mg, 70%) in CH₂Cl₂ (54 μL) was added. After being stirred for 45 min, the reaction was quenched by addition of Et₃N (5 μL), and then the mixture was warmed to r.t., diluted with CH₂Cl₂ (10 mL), and washed with sat. aq. NaHCO₃ (5 mL) and brine (5 mL). The organic phase was dried over Na₂SO₄ and concentrated. The residue was purified by HPLC (two consecutive columns: toluene–EtOAc, 10:1→5:1→1:1 followed by hexane–EtOAc, 2:1→1:1, column B) to afford **61** (11 mg, 5 μmol , 89%) as a syrup: R_f = 0.53 (hexane–EtOAc, 1:1); $[\alpha]_D^{20}$ = +31 (c 1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.38–7.21 (m, 30H, CH₂Ph), 6.46 (d, 1H, ³J_{NH,2} = 8.3 Hz, NH), 5.30 (t, 1H, ³J_{4,3'} = ³J_{4,5'} = 9.8 Hz, H-4'), 5.23–5.16 (m, 3H, H-3, 2 \times β^{Myr} -CH), 5.15 (d, 1H, ³J_{1,2} = 3.7 Hz, H-1), 5.10 (d, 1H, ³J_{1,2'} = 2.0 Hz, H-1'), 5.10–5.06 (m, 1H, β^{Myr} -CH), 5.03–4.93 (m, 8H, 2 \times OP(O)(OCH₂Ph)₂), 4.67 (AB, 1H, ²J = 12.1 Hz, CH₂Ph), 4.63 (AB, 1H, ²J = 12.1 Hz, CH₂Ph), 4.45 (AB, 1H, ²J = 11.8 Hz, CH₂Ph), 4.43–4.39 (m, 1H, H-4), 4.38 (AB, 1H, ²J = 11.9 Hz, CH₂Ph), 4.30–4.26 (m, 1H, H-2), 4.07–4.04 (m, 2H, H-6a', H-6b'), 4.01 (dd, 1H, ³J_{3,2'} = 3.0 Hz, ³J_{3,4'} = 9.6 Hz, H-

4'), 3.89–3.86 (m, 1H, H-5'), 3.74 (dd, 1H, ³J_{6a,5} = 1.7 Hz, ²J_{6a,6b} = 10.8 Hz, H-6a), 3.72–3.69 (m, 1H, H-5), 3.56 (dd, 1H, ³J_{6b,5} = 5.9 Hz, ²J_{6b,6a} = 10.8 Hz, H-6b), 3.28 (t, 1H, ²J = 2.6 Hz, H-2'), 3.23 (s, 3H, CH₃, Me), 2.58–2.52 (m, 3H, α^{Myr} -CH₂), 2.48–2.44 (m, 2H, α^{Myr} -CH₂), 2.41–2.38 (m, 1H, α^{Myr} -CH₂), 2.34–2.24 (m, 2H, α^{Lau} -CH₂), 2.20–2.16 (m, 4H, α^{Lau} -CH₂, α^{Myr} -CH₂), 1.61–1.49 (m, 12H, β^{Myr} -CH₂, 2 \times β^{Lau} -CH₂, 3 \times γ^{Myr} -CH₂), 1.29–1.22 (m, 106H, 53 \times CH₂), 0.89–0.86 (m, 18H, 4 \times ω^{Myr} -CH₃, 2 \times ω^{Lau} -CH₃); ¹³C NMR (151 MHz, CDCl₃) δ 173.89, 173.25, 172.94, 171.20, 169.77, 169.07 (6 \times CO), 137.99, 137.85 (2 \times Cq, CH₂Ph), 135.98, 135.94, 135.56, 135.51 (4 \times Cq, OP(O)(OCH₂Ph)₂), 128.69, 128.63, 128.54, 128.46, 128.44, 128.30, 128.28, 128.14, 128.02, 127.96, 127.92, 127.88, 127.64, 127.60 (30 \times CH, CH₂Ph), 93.36 (C-1'), 93.18 (C-1), 77.55 (C-2'), 75.96 (C-3'), 73.69 (C-4, ²J_{C₄,P} = 6.1 Hz), 73.49, 72.47 (2 \times CH₂, Ph), 71.24, 70.96, 70.66, 70.60, 69.82, 69.76 (C-3, C-5, C-5', β^{Myr} -CH, 2 \times β^{Lau} -CH), 69.78, 69.74, 69.70, 69.32 (4 \times CH₂, OP(O)(OCH₂Ph)₂), 68.48 (C-6), 67.50 (C-4'), 66.15 (C-6'), 59.02 (CH₃, Me), 51.44 (C-2), 41.56, 38.96, 38.77 (3 \times α^{Myr} -CH₂), 34.77, 34.55, 34.41, 34.20, 34.00 (α^{Myr} -CH₂, 2 \times α^{Lau} -CH₂, 3 \times γ^{Myr} -CH₂), 31.94, 31.92, 29.75, 29.73, 29.69, 29.67, 29.65, 29.63, 29.56, 29.54, 29.51, 29.47, 29.39, 29.36, 29.31, 29.19, 25.37, 25.17, 25.12, 25.01, 22.68 (56 \times CH₂), 14.09 (4 \times ω^{Myr} -CH₃, 2 \times ω^{Lau} -CH₃); ³¹P NMR (243 MHz, CDCl₃) δ -1.61, -1.69; HRMS (ESI) m/z calcd for C₁₃₅H₂₁₁NO₂₅P₂+Na⁺ 2331.4638 [M+Na⁺], found 2331.4618.

4-O-[(R)-3-(Dodecanoyloxy)tetradecanoyl]-2-O-methyl-6-O-phosphoryl- α -D-mannopyranosyl-(1 \leftrightarrow 1)-2-deoxy-2-[(R)-3-(dodecanoyloxy)tetradecanoylamino]-4-O-phosphoryl-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]- α -D-glucopyranoside (1**).** A solution of **61** (10 mg, 4.3 μmol) in toluene–MeOH (1 mL, 1:1) was hydrogenated over Pd-black (5 mg, 47 μmol) for 20 h. The mixture was diluted with CH₂Cl₂–EtOH (1:1, 10 mL), and the solids were removed by filtration (syringe filter, regenerated cellulose, 45 μm). The filtrate was concentrated, and the residue was purified by size exclusion chromatography on Bio-Beads SX1 (200–400 mesh, 2 \times 60 cm, toluene–CH₂Cl₂, 3:1). Appropriate fractions were concentrated, and the residue was dissolved in DMSO (2 mL) and freeze-dried to afford **1** (6.0 mg, 3.4 μmol , 79%) as a white solid: R_f = 0.29 (CHCl₃–MeOH–H₂O, 50:28:6); ¹H NMR (600 MHz, CDCl₃–MeOD, 3:1) δ 5.29 (d, 1H, ³J_{1,2} = 3.8 Hz, H-1), 5.27–5.22 (m, 4H, H-1', H-3, 2 \times β^{Myr} -CH), 5.14–5.09 (m, 1H, β^{Myr} -CH), 5.00 (t, 1H, ³J_{4,3'} = ³J_{4,5'} = 9.7 Hz, H-4'), 4.31 (dt, 1H, ³J = 9.7 Hz, ²J = 9.9 Hz, H-4), 4.17 (dd, 1H, ³J_{2,1} = 3.7 Hz, ³J_{2,3} = 10.9 Hz, H-2), 4.03 (dd, 1H, ³J_{3,2'} = 3.6 Hz, ³J_{3,4'} = 9.5 Hz, H-3'), 4.02–3.98 (m, 1H, H-6a'), 3.94–3.87 (m, 2H, H-6a, H-6b'), 3.79–3.75 (m, 2H, H-5', H-6b), 3.73–3.69 (m, 1H, H-5), 3.49 (dd, 1H, ³J_{2,1'} = 1.8 Hz, ³J_{2,3'} = 3.5 Hz, H-2'), 3.48 (s, 3H, CH₃, Me), 2.68–2.60 (m, 4H, 2 \times α^{Myr} -CH₂), 2.52–2.45 (m, 2H, α^{Myr} -CH₂), 2.33–2.29 (m, 6H, α^{Myr} -CH₂, 2 \times α^{Lau} -CH₂), 1.67–1.54 (m, 12H, β^{Myr} -CH₂, 2 \times β^{Lau} -CH₂, 3 \times γ^{Myr} -CH₂), 1.35–1.23 (m, 106H, 53 \times CH₂), 0.89 (t, 18H, ²J = 7.0 Hz, 4 \times ω^{Myr} -CH₃, 2 \times ω^{Lau} -CH₃); ³¹P NMR (243 MHz, CDCl₃–MeOD, 3:1) δ 0.38, 0.01; MS (MALDI) m/z calcd for C₉₅H₁₇₅NO₂₅P–H 1767.186 [M–H][–], found 1767.058. For MALDI-TOF MS, 1 μL of a solution of **1** (0.5 mg/mL in CH₂Cl₂–EtOH, 1:1) was mixed with 6-aza-2-thiothymine matrix (3 mg/mL EtOH–20 mM aq. ammonium citrate buffer, 1:1).

4-O-[(R)-3-(Decanoyloxy)tetradecanoyl]-2-O-methyl-6-O-phosphoryl- α -mannopyranosyl-(1 \leftrightarrow 1)-2-deoxy-2-[(R)-3-(dodecanoyloxy)tetradecanoylamino]-4-O-phosphoryl-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]- α -D-glucopyranoside (2**).** Compound **2** (12 mg, 5.3 μmol) was prepared from **62** in a manner similar to the synthesis of **1**, which afforded **2** (8.0 mg, 4.6 μmol , 87%) as a white fluffy solid: R_f = 0.38 (CHCl₃–MeOH–H₂O, 50:28:6); ¹H NMR (600 MHz, CDCl₃–MeOD, 3:1) δ 5.29 (d, 1H, ³J_{1,2} = 3.6 Hz, H-1), 5.27–5.21 (m, 4H, H-1', H-3, 2 \times β^{Myr} -CH), 5.14–5.09 (m, 1H, β^{Myr} -CH), 5.00 (t, 1H, ³J_{4,3'} = ³J_{4,5'} = 9.7 Hz, H-4'), 4.31 (dt, 1H, ³J_{4,5} = ³J_{4,3} = ³J_{4,P} = 9.7 Hz, H-4), 4.19–4.13 (m, 1H, H-2), 4.03 (dd, 1H, ³J_{3,2'} = 3.5 Hz, ³J_{3,4'} = 9.5 Hz, H-3'), 4.01–3.98 (m, 1H, H-6a'), 3.94–3.88 (m, 2H, H-6a, H-6b'), 3.79–3.74 (m, 2H, H-5', H-6b), 3.73–3.69 (m, 1H, H-5), 3.49 (dd, 1H, ³J_{2,1'} = 1.8 Hz, ³J_{2,3'} = 3.4 Hz, H-2'), 3.48 (s, 3H, CH₃, Me), 2.70–2.60 (m, 4H, 2 \times α^{Myr} -CH₂), 2.52–2.45 (m, 2H, α^{Myr} -CH₂), 2.33–2.29 (m, 6H, α^{Myr} -CH₂, α^{Lau} -CH₂, α^{Cap} -CH₂),

1.65–1.55 (m, 12H, $3\times\gamma$ Myr -CH₂, β^{Myr} -CH₂, β^{Lau} -CH₂, β^{Cap} -CH₂), 1.37–1.22 (m, 102H, $51\times$ CH₂), 0.89 (t, 18H, $J = 7.0$ Hz, $4\times\omega$ Myr -CH₃, ω^{Lau} -CH₃, ω^{Cap} -CH₃); ³¹P NMR (243 MHz, CDCl₃-MeOD, 3:1) δ 0.42, 0.01; MS (MALDI) m/z calcd for C₉₁H₁₇₁NO₂₅P₂-H 1739.154 [M-H]⁻, found 1739.160.

4-O-[(R)-3-(Dodecanoyloxy)tetradecanoyl]-2-O-methyl- α -D-mannopyranosyl-(1 \leftrightarrow 1)-2-deoxy-2-[(R)-3-(dodecanoyloxy)-tetradecanoylamino]-4-O-phosphoryl-3-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]- α -D-glucopyranoside (3). Compound 3 (5.6 mg, 2.7 μ mol) was prepared from 57 in a manner similar to the synthesis of 1, which afforded 3 (3.7 mg, 2.2 μ mol, 81%) as a white fluffy solid: $R_f = 0.47$ (CHCl₃-MeOH-H₂O, 50:28:6); ¹H NMR (600 MHz, CDCl₃-MeOD, 3:1) δ 7.16 (d, 1H, $^3J_{NH,2} = 8.3$ Hz, NH), 5.26–5.17 (m, 5H, H-1, H-1', H-3, $2\times\beta^{Myr}$ -CH), 5.12–5.08 (m, 1H, β^{Myr} -CH), 5.04 (t, 1H, $^3J_{4',3'} = ^3J_{4',5'} = 9.8$ Hz, H-4'), 4.30 (dt, 1H, $^3J_{4,5} = ^3J_{4,3} = ^3J_{4,P} = 9.9$ Hz, H-4), 4.24–4.19 (m, 1H, H-2), 4.04 (dd, 1H, $^3J_{3,2'} = 3.5$ Hz, $^3J_{3',4'} = 9.6$ Hz, H-3'), 3.94 (dd, 1H, $J = 2.9$ Hz, $J = 13.0$ Hz, H-6a), 3.75–3.71 (m, 1H, H-6b), 3.71–3.67 (m, 1H, H-5), 3.66–3.62 (m, 1H, H-5'), 3.57–3.54 (m, 2H, H-6a', H-6b'), 3.51–3.48 (m, 1H, H-2'), 3.49 (s, 3H, CH₃, Me), 2.69–2.58 (m, 4H, $2\times\alpha^{Myr}$ -CH₂), 2.49 (dd, 1H, $J = 6.9$ Hz, $J = 14.9$ Hz, α^{Myr} -CH₂), 2.43 (dd, 1H, $J = 5.9$ Hz, $J = 14.9$ Hz, α^{Myr} -CH₂), 2.32–2.28 (m, 6H, α^{Myr} -CH₂, $2\times\alpha^{Lau}$ -CH₂), 1.67–1.54 (m, 12H, β^{Myr} -CH₂, $2\times\beta^{Lau}$ -CH₂, $3\times\gamma^{Myr}$ -CH₂), 1.38–1.22 (m, 106H, $53\times$ CH₂), 0.89 (t, 18, $J = 7.0$ Hz, $4\times\omega^{Myr}$ -CH₃, $2\times\omega^{Lau}$ -CH₃); ³¹P NMR (243 MHz, CDCl₃-MeOD, 3:1) δ 0.68; MS (ESI) m/z calcd for C₉₃H₁₇₄NO₂₂P-H 1687.219 [M-H]⁻, found 1687.205.

Biological Assays. Reagents. HEK293 stably expressing human TLR4, MD-2, CD14, and a secreted NF- κ B-dependent reporter (HEKBlue hTLR4), *E. coli* O111:B4 LPS, *E. coli* serotype R515 Re-LPS, *S. minnesota* R595 MPLA (SM-MPLA), and synthetic *E. coli* lipid A were purchased from InvivoGen. Synthetic *E. coli* lipid A was purchased from Peptide Institute. The THP-1 human monocyte-like cell line was obtained from Dr. Rene Devos (Roche Research Ghent) and originally purchased from ATCC. The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) was purchased from Sigma. Lipid A mimetics 1–3 were reconstituted in DMSO to provide 1 mg/mL stock solutions. Further dilutions were made with cell medium (RPMI or DMEM) supplemented with 10% FCS so that the final amount of DMSO in the cell culture did not exceed 0.01%.

hTLR4/MD-2/CD14-Transfected HEK293 Cells (Hek-Blue) Activation Assay. Growth conditions and activation assay were set as recommended by InvivoGen. The cells were stimulated with the solutions of compounds 1–3 or LPS/Re-LPS in DMEM supplemented by 10% FCS at the indicated concentrations. The final amount of DMSO in the cell culture did not exceed 0.005% for 1 and 2 or 0.01% for 3. The compounds were added in a total volume of 20 μ L to 25000 HEK-Blue hTLR4 cells in 180 μ L plates and were incubated for 20–24 h at 37 °C and 5% CO₂. SEAP levels were determined by incubation of 20 μ L of challenged cell supernatants with 180 μ L of detection reagent (QUANTI-Blue), and the color development was measured at 650 nm using a spectrophotometer (SpectraMAX 190). Data were combined from $n = 3$ independent experiments; error bars indicate standard error of the mean.

Differentiation and Stimulation of THP-1 Cells. THP-1 cells were grown in RPMI-1640 cell-culture medium (Life Technologies) that was supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 μ g/mL streptomycin, and 10% FCS. Cells were seeded in a 96-well plate at 10⁵ cells/well in 150 μ L of complete medium and stimulated by 200 nM TPA for 24 h to induce the differentiation into macrophage-like cells.⁵⁹ On the next day the cells were washed twice with complete culture medium to discard the cells that did not adhere, refreshed with 200 μ L of complete medium, and left for 1 h to recover. Cells were stimulated with α,α -GM-LAMs 1–3 at the indicated concentration and with *E. coli* Re-LPS (or *E. coli* O111:B4 LPS), which were added as solutions in 10 μ L of complete medium. The total volume of the well after stimulation reached 220 μ L. The cells were incubated for 18 h, and the supernatants were analyzed for TNF- α , IL-8, and MCP-1 by ELISA (BD Biosciences).

Activation of Mouse Bone Marrow-Derived Macrophages by α,α -GM-LAMs 1–3. Bone-marrow-derived macrophages (BMDMs) were isolated and differentiated from the bone marrow of C57BL/6J mice. The bone marrow was flushed from femur and tibia with RPMI media. The erythrocytes were lysed with 0.88% ammonium chloride, 15 min at 37 °C. A single-cell suspension of the bone marrow cells was then seeded in cell culture flasks at a concentration of 1 \times 10⁶ cells/mL in RPMI supplemented with 20% FBS and 40 ng/mL recombinant M-CSF. The cell culture medium was changed on day 3. On day 6, the differentiated cells were trypsinized, counted, and seeded in 24-well plates at a concentration of 1 \times 10⁶ cells/mL in RPMI supplemented with 10% FBS. After 24 h, the cells were stimulated with Lipid A mimetics 1–3 and with synthetic *E. coli* Lipid A/MPLA (*E. coli* O111:B4 LPS was used as positive control) for 16 h. The nanomolar concentrations of 1–3 were calculated according to the MW of the synthetic compounds. The supernatants were then tested for cytokines using Ready-Set-Go ELISA kits (eBioscience).

Induction of Cytokine Production by α,α -GM-LAMs 1 and 3 in hDCs. Human peripheral blood monocytes were cultured for 6 days in GM-CSF and IL-4 to receive immature monocyte-derived DCs and were then stimulated with the indicated concentrations of 1 and 3 using 10 ng/mL LPS as positive control (solutions in PRMI containing 10% FCS and 0.005–0.01% DMSO). The amounts of IL-6, IL-12, IL-10, and TNF- α in the supernatants of the cells were analyzed after 24 h by Luminex. Results are representative of three independent experiments for 1 and of two experiments for 3. Mean values of duplicate examinations \pm SD are presented.

■ ASSOCIATED CONTENT

Supporting Information

Supplementary tables and figures, experimental procedures, and ¹H NMR, ¹³C NMR, and MALDI-TOF spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Phone: +431 47654 6084. E-mail: alla.zamyatina@boku.ac.at.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support from Austrian Science Foundation (grant FWF P-22116) is gratefully acknowledged. We thank Dr. Andreas Hofinger for support with NMR measurements.

■ ABBREVIATIONS USED

TLR4, Toll-like Receptor 4; MD-2, myeloid differentiation factor 2; α,α -GM-LAM, α GlcN(1 \leftrightarrow 1) α Man-based Lipid A mimetic; MPLA, synthetic *E. coli* monophosphoryl Lipid A; SM-MPLA, *S. minnesota* monophosphoryl Lipid A; MyD88, myeloid differentiation primary response gene 88

■ REFERENCES

- (1) Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat. Immunol.* **2010**, *5*, 373–384.
- (2) Opal, S. M. The host response to endotoxin, antilipoplysaccharide strategies, and the management of severe sepsis. *Int. J. Med. Microbiol.* **2007**, *5*, 365–377.
- (3) Hammad, H.; Chieppa, M.; Perros, F.; Willart, M. A.; Germain, R. N.; Lambrecht, B. N. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. *Nat. Med.* **2009**, *4*, 410–416.
- (4) Reisser, D.; Jeannin, J.-F. Lipid A in cancer therapies: preclinical studies. In *Lipid A in cancer therapy*; Jeannin, J.-F., Ed.; Springer, Landes Bioscience: New York, 2009; pp 101–110.

- (5) Gangloff, M.; Gay, N. J. MD-2: the Toll 'gatekeeper' in endotoxin signalling. *Trends Biochem. Sci.* **2004**, *6*, 294–300.
- (6) Hotchkiss, R. S.; Monneret, G.; Payen, D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. *Nat. Rev. Immunol.* **2013**, *12*, 862–874.
- (7) Iwasaki, A.; Medzhitov, R. Toll-like receptor control of the adaptive immune responses. *Nat. Immunol.* **2004**, *10*, 987–995.
- (8) Casella, C.; Mitchell, T. Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant. *Cell. Mol. Life Sci.* **2008**, *20*, 3231–3240.
- (9) Ishizaka, S. T.; Hawkins, L. D. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. *Exp. Rev. Vaccines* **2007**, *5*, 773–784.
- (10) Johnson, D. A. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. *Curr. Top. Med. Chem.* **2008**, *2*, 64–79.
- (11) Bryant, C. E.; Spring, D. R.; Gangloff, M.; Gay, N. J. The molecular basis of the host response to lipopolysaccharide. *Nat. Rev. Microbiol.* **2010**, *1*, 8–14.
- (12) Ohto, U.; Fukase, K.; Miyake, K.; Satow, Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. *Science* **2007**, *5831*, 1632–1634.
- (13) Kim, H. M.; Park, B. S.; Kim, J.-I.; Kim, S. E.; Lee, J.; Oh, S. C.; Enkhbayar, P.; Matsushima, N.; Lee, h.; Yoo, O. J.; Lee, J.-O. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. *Cell* **2007**, *906*–917.
- (14) Park, B. S.; Song, D. H.; Kim, H. M.; Choi, B. S.; Lee, H.; Lee, J. O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature* **2009**, *1191*–1195.
- (15) Ohto, U.; Fukase, K.; Miyake, K.; Shimizu, T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *19*, 7421–7426.
- (16) Yu, L.; Phillips, R. L.; Zhang, D.; Teghanemt, A.; Weiss, J. P.; Giannini, T. L. NMR studies of hexaacetylated endotoxin bound to wild-type and F126A mutant MD-2 and MD-2-TLR4 ectodomain complexes. *J. Biol. Chem.* **2012**, *20*, 16346–16355.
- (17) Teghanemt, A.; Re, F.; Prohinar, P.; Widstrom, R.; Giannini, T. L.; Weiss, J. P. Novel roles in human MD-2 of Phenylalanines 121 and 126 and Tyrosine 131 in activation of Toll-like receptor 4 by endotoxin. *J. Biol. Chem.* **2008**, *3*, 1257–1266.
- (18) Kumar, H.; Kawai, T.; Akira, S. Toll-like receptors and innate immunity. *Biochem. Biophys. Res. Commun.* **2009**, *4*, 621–625.
- (19) Meng, J.; Lien, E.; Golenbock, D. T. MD-2-mediated ionic interactions between Lipid A and TLR4 are essential for receptor activation. *J. Biol. Chem.* **2010**, *12*, 8695–8702.
- (20) Casella, C. R.; Mitchell, T. C. Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A. *PLoS One* **2013**, *4*, No. e62622.
- (21) Tanimura, N.; Saitoh, S. i.; Ohto, U.; Akashi-Takamura, S.; Fujimoto, Y.; Fukase, K.; Shimizu, T.; Miyake, K. The attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of the TLR4/MD2 complex at the plasma membrane. *Int. Immunol.* **2014**, *6*, 307–314.
- (22) Trent, M. S.; Stead, C. M.; Tran, A. X.; Hankins, J. V. Diversity of endotoxin and its impact on pathogenesis. *J. Endotoxin Res.* **2006**, *4*, 205–223.
- (23) Zughair, S. M.; Zimmer, S. M.; Datta, A.; Carlson, R. W.; Stephens, D. S. Differential induction of the Toll-Like Receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. *Infect. Immun.* **2005**, *5*, 2940–2950.
- (24) Needham, B. D.; Carroll, S. M.; Giles, D. K.; Georgiou, G.; Whiteley, M.; Trent, M. S. Modulating the innate immune response by combinatorial engineering of endotoxin. *Proc. Natl. Acad. Sci. U.S.A.* **2013**, *4*, 1464–1469.
- (25) Fujimoto, Y.; Adachi, Y.; Akamatsu, M.; Fukase, Y.; Kataoka, M.; Suda, Y.; Fukase, K.; Kusumoto, S. Synthesis of lipid A and its analogues for investigation of the structural basis for their bioactivity. *J. Endotoxin Res.* **2005**, *6*, 341–347.
- (26) Zhang, Y.; Gaekwad, J.; Wolfert, M. A.; Boons, G. J. Modulation of innate immune responses with synthetic Lipid A derivatives. *J. Am. Chem. Soc.* **2007**, *16*, 5200–5216.
- (27) Akamatsu, M.; Fujimoto, Y.; Kataoka, M.; Suda, Y.; Kusumoto, S.; Fukase, K. Synthesis of lipid A monosaccharide analogues containing acidic amino acid: exploring the structural basis for the endotoxic and antagonistic activities. *Bioorg. Med. Chem.* **2006**, *19*, 6759–6777.
- (28) Zhang, Y.; Gaekwad, J.; Wolfert, M. A.; Boons, G. J. Innate immune responses of synthetic lipid A derivatives of *Neisseria meningitidis*. *Chem.—Eur. J.* **2007**, *2*, 558–569.
- (29) Peri, F.; Calabrese, V. Toll-like Receptor 4 (TLR4) modulation by synthetic and natural compounds: an update. *J. Med. Chem.* **2013**, *9*, 3612–3622.
- (30) Bazin, H. G.; Bess, L. S.; Livesay, M. T.; Ryter, K. T.; Johnson, C. L.; Arnold, J. S.; Johnson, D. A. New synthesis of glycolipid immunostimulants RC-529 and CRX-524. *Tetrahedron Lett.* **2006**, *13*, 2087–2092.
- (31) Artner, D.; Oblak, A.; Ittig, S.; Garate, J. A.; Horvat, S.; Arrieumerlou, C.; Hofinger, A.; Oostenbrink, C.; Jerala, R.; Kosma, P.; Zamyatina, A. Conformationally constrained Lipid A mimetics for exploration of structural basis of TLR4/MD-2 activation by lipopolysaccharide. *ACS Chem. Biol.* **2013**, *11*, 2423–2432.
- (32) Needham, B. D.; Trent, M. S. Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. *Nat. Rev. Microbiol.* **2013**, *7*, 467–481.
- (33) French, A. D.; Johnson, G. P.; Kelterer, A. M.; Dowd, M. K.; Cramer, C. J. Quantum mechanics studies of the intrinsic conformation of trehalose. *J. Phys. Chem. A* **2002**, *106*, 4988–4997.
- (34) Nunes, S. C. C.; Jesus, A. J. L.; Moreno, M. J.; Eusebio, M. E. Conformational preferences of α,α -trehalose in gas phase and aqueous solution. *Carbohydr. Res.* **2010**, *14*, 2048–2059.
- (35) Färnbäck, M.; Eriksson, L.; Widmalm, G. Octa-O-acetyl- α,α -trehalose ethanol disolvate. *Acta Crystallogr. Sect. E* **2004**, 1483–1485.
- (36) Bock, K.; Defaye, J.; Driguez, H.; Bar-Guilloux, E. Conformations in solution of α,α -trehalose, α -D-glucopyranosyl α -D-mannopyranoside, and their 1-thioglycosyl analogs, and a tentative correlation of their behaviour with respect to the enzyme trehalase. *Eur. J. Biochem.* **1983**, *595*–600.
- (37) Brown, G. M.; Rohrer, D. C.; Berking, B.; Beevers, C. A.; Gould, R. O.; Simpson, R. The crystal structure of α,α -trehalose dihydrate from three independent X-ray determinations. *Acta Crystallogr. Sect. B* **1972**, *3145*–3158.
- (38) Chaube, M. A.; Kulkarni, S. S. Stereoselective construction of 1,1- α,α -glycosidic bond. *Trends Carbohydr. Res.* **2012**, *2*, 1–19.
- (39) Leigh, C. D.; Bertozzi, C. R. Synthetic studies toward *Mycobacterium tuberculosis* Sulfolipid-1. *J. Org. Chem.* **2008**, *3*, 1008–1017.
- (40) Paul, N. K.; Twibanire, J. d.; Grindley, T. B. Direct synthesis of maradolipids and other trehalose 6-monoesters and 6,6'-diesters. *J. Org. Chem.* **2012**, *2*, 363–369.
- (41) Kunz, H.; Zimmer, J. Glycoside synthesis via electrophile-induced activation of N-allyl carbamates. *Tetrahedron Lett.* **1993**, *18*, 2907–2910.
- (42) Saibal, K. D.; Roy, N. An improved method for the preparation of some ethyl 1-thioglycosides. *Carbohydr. Res.* **1996**, *1–4*, 275–277.
- (43) Yu, B.; Sun, J. Glycosylation with glycosyl N-phenyltrifluoroacetimidates (PTFAI) and a perspective of the future development of new glycosylation methods. *Chem. Commun.* **2010**, *26*, 4668–4679.
- (44) Hölemann, A.; Stocker, B. L.; Seeberger, P. H. Synthesis of a core arabinomannan oligosaccharide of *Mycobacterium tuberculosis*. *J. Org. Chem.* **2006**, *21*, 8071–8088.
- (45) Boltje, T. J.; Zhong, W.; Park, J.; Wolfert, M. A.; Chen, W.; Boons, G. J. Chemical synthesis and immunological evaluation of the inner core oligosaccharide of *Francisella tularensis*. *J. Am. Chem. Soc.* **2012**, *134*, 14255–14262.
- (46) Jensen, H. H.; Nordstrom, L. U.; Bols, M. The disarming effect of the 4,6-acetal group on glycoside reactivity: torsional or electronic? *J. Am. Chem. Soc.* **2004**, *126*, 9205–9213.

(47) Walvoort, M. T. C.; de Witte, W.; van Dijk, J.; Dinkelaar, J.; Lodder, G.; Overkleeft, H. S.; Codée, J. D. C.; van der Marel, G. A. Mannopyranosyl uronic acid donor reactivity. *Org. Lett.* **2011**, *16*, 4360–4363.

(48) Tanifum, C. T.; Chang, C. W. Sonication-assisted oligomannoside synthesis. *J. Org. Chem.* **2008**, *2*, 634–644.

(49) Geng, X.; Dudkin, V. Y.; Mandal, M.; Danishefsky, S. J. In pursuit of carbohydrate-based HIV vaccines. Part 2: the total synthesis of high-mannose-type gp120 fragments: evaluation of strategies directed to maximal convergence. *Angew. Chem., Int. Ed.* **2004**, *19*, 2562–2565.

(50) Bock, K.; Lundt, I.; Pedersen, C. Assignment of anomeric structure to carbohydrates through geminal ^{13}C -H coupling constants. *Tetrahedron Lett.* **1973**, *13*, 1037–1040.

(51) Bubbs, W. A. NMR spectroscopy in the study of carbohydrates: Characterizing the structural complexity. *Concepts Magn. Reson., Part A* **2003**, *1*, 1–19.

(52) Coxon, B. Developments in the Karplus equation as they relate to the NMR coupling constants of carbohydrates. In *Advances in Carbohydrate Chemistry and Biochemistry*, Vol. 62; Derek, H., Ed.; Academic Press: New York, 2009; pp 17–82.

(53) Duynstee, H. I.; van Vliet, M. J.; van der Marel, G. A.; van Boom, J. H. An efficient synthesis of (R)-3-[(R)-3-[2-O-(α -L-rhamnopyranosyl)- α -L-rhamnopyranosyl]oxydecanoyl]oxydecanoic acid, a rhamnolipid from *Pseudomonas Aeruginosa*. *Eur. J. Org. Chem.* **1998**, *2*, 303–307.

(54) Kusumoto, S.; Fukase, K. Synthesis of endotoxic principle of bacterial lipopolysaccharide and its recognition by the innate immune systems of hosts. *Chem. Rec.* **2006**, *6*, 333–343.

(55) Raetz, C. R. H.; Garrett, T. A.; Reynolds, C. M.; Shaw, W. A.; Moore, J. D.; Smith, D. C., Jr.; Ribeiro, A. A.; Murphy, R. C.; Ulevitch, R. J.; Fearn, C.; Reichart, D.; Glass, C. K.; Benner, C.; Subramaniam, S.; Harkewicz, R.; Bowers-Gentry, R. C.; Buczynski, M. W.; Cooper, J. A.; Deems, R. A.; Dennis, E. A. Kdo2-Lipid A of *E. coli*, a defined endotoxin that activates macrophages via TLR-4. *J. Lipid Res.* **2006**, *5*, 1097–1111.

(56) Shibata, T.; Motoi, Y.; Tanimura, N.; Yamakawa, N.; Akashi-Takamura, S.; Miyake, K. Intracellular TLR4/MD-2 in macrophages senses Gram-negative bacteria and induces a unique set of LPS-dependent genes. *Int. Immunol.* **2011**, *8*, 503–510.

(57) Re, F.; Strominger, J. L. Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. *Immunobiology* **2004**, *1–2*, 191–198.

(58) Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. *Nat. Rev. Immunol.* **2003**, *2*, 133–146.

(59) Tsuchiya, S.; Kobayashi, Y.; Goto, Y.; Okumura, H.; Nakae, S.; Konno, T.; Tada, K. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. *Cancer Res.* **1982**, *4*, 1530–1536.